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Abstract
Pharmacological Characterization of an Optimized Sigma Receptor Ligand
Michael Seminerio

Methamphetamine is an addictive psychostimulant drug with an increasing prevalence of
abuse worldwide. Recent evidence has linked methamphetamine exposure to a wide array of
neurological complications some of which lead to neurodegenerative changes in the brain and
hyperthermia. Currently, there are no FDA approved pharmacologic agents to treat the effects
of methamphetamine. Recent evidence has suggested methamphetamine may, in part, produce
some of its effects through sigma receptors making them a potential target for pharmacological
intervention. While our lab has shown a number of selective sigma receptor ligands can provide
neuroprotection against the neurotoxic and behavioral effects of methamphetamine, limitations
such as metabolic instability have prevented the advancement of any lead compound to ladder
drug development studies. To address this issue and pursue a lead therapeutic compound to
aid against methamphetamine-induced complications, CM156, a previously studied selective
sigma receptor ligand, was optimized for metabolic stability. Following the synthesis and
evaluation of thirty CM156 analogs, a lead compound was identified. Radioligand binding
studies demonstrated the lead analog, AZ66, displayed high nanomolar affinity for both sigma-1
and sigma-2 receptors (2.4 ± 0.63 and 0.51 ± 0.15, respectively). In addition, AZ66 had
preferential affinity for sigma receptors compared to sixty-four other sites and a significantly
longer half life than its predecessor, CM156, in vitro and in vivo. To further characterize AZ66 as
a potential lead compound, we evaluated AZ66 against the neurotoxic, behavioral, and cognitive
effects produced by methamphetamine. Pretreatment of male, Swiss Webster mice with
intraperitoneal (10-20 mg/kg) or oral (20-30 mg/kg)dosing of AZ66significantly attenuated the
acute locomotor stimulatory effects of methamphetamine in addition to reducing the expression
and development of behavioral sensitization induced by repeated methamphetamine
administration. Furthermore, AZ66 significantly attenuated methamphetamine-induced striatal
dopamine depletions, striatal dopamine transporter reductions, and hyperthermia. Additionally,
neurotoxic dosing with methamphetamine caused significant memory impairment in the object
recognition test which was attenuated when animals were pretreated with AZ66; similar trends
were observed in the step-through passive avoidance test. The studies presented herein
demonstrate that targeting sigma receptors can provide neuroprotective effects against
methamphetamine and AZ66 may represent a promising lead compound for developing future
therapeutics.
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CHAPTER 1
BACKGROUND AND OBJECTIVES

1

1.1 Methamphetamine
Methamphetamine, also referred to as methylamphetamine, N-methylamphetamine,
desoxyephedrine, phenylisopropylmethylamine, and street names speed, meth, ice, crank,
crystal and chalk, is a methylated analogue of amphetamine thought to act primarily on the
central nervous system (Schep et al., 2010). Originally used therapeutically to treat obesity and
attention deficit disorder, methamphetamine is now a schedule II drug rarely used in the clinic.
Methamphetamine abuse has become a worldwide public health issue and is the second most
commonly used illegal drug in the world(Cruickshank and Dyer, 2009; Krasnova and Cadet,
2009). Because of its ease of synthesis from over-the-counter drugs, long duration of action,
and relatively low cost, methamphetamine is widely available and easily accessible. This is
evident by the estimated 290 tons of methamphetamine synthesized in 2005 worldwide, an
amount equivalent to 2.9 billion 100-mg doses(Cruickshank and Dyer, 2009). Use and public
awareness appears to be increasing worldwide as amphetamine-type stimulant (ATS) seizures
have reached a record high globally, much of this attributed to a rise in methamphetamine
seizures, particularly in North America, Asia, and Oceania(Crime, 2011). Over 12 million
Americans have used methamphetamine at least once in their life and there are roughly 16
million users worldwide, a number which exceeds that of combined heroin and cocaine
users(United Nations, 2007). In 2005, an estimated 20-40 billion dollars was spent on
methamphetamine-related complications stemming from addiction, premature death, and
psychological treatment (Dobkin and Nicosia, 2009). However, due to a large gap in our
understanding of the mechanisms behind methamphetamine, the field is currently lacking a
proven pharmacologic agent to treat methamphetamine-induced complications. With a steady
and annual increase of treatment admissions for methamphetamine (Roehr, 2005), the
development of an effective therapeutic agent would result in significant health and economic
benefits.
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1.1.2. Pharmacokinetics of Methamphetamine. The pharmacokinetics of
methamphetamine are important to consider as varying routes can display increased or
decreased effects. Methamphetamine is used through four primary routes – intravenous,
inhalation (smoking), oral, and intra-nasal. Route of use dictates bioavailability with studies
demonstrating oral administration resulting in the lowest bioavailability (67%) and intravenous
administration resulting in the greatest bioavailability (100%) (Schep et al., 2010). Intranasal
(79%) and smoking (67-90%), depending on technique utilized, fall in between(Cruickshank and
Dyer, 2009). Similarly, as would be expected, route of administration determines time to peak
effect as well. Intravenous and intranasal dosing results in peak effects within the first 15
minutes while smoking demonstrates a slightly longer time-to-peak of 18 minutes and lastly, oral
uptake results in a significant delay of approximately 3 hours(Cruickshank and Dyer, 2009).
Alternative routes of administration, for which little to no pharmacokinetic data exist, have
emerged in recent years and require further investigation to elucidate drug uptake. These
include body stuffing in which poorly packaged drugs are ingested, usually in an attempt to
avoid prosecution by the police; ‘parachuting’ in which the drug is placed into a plastic bag with
the seal removed, rolled tightly, and swallowed, theoretically releasing the drug over a
prolonged period; and ‘shelving’, also known as intra vaginal stuffing (Hendrickson et al., 2006;
Kashani and Ruha, 2004; West et al., 2010). Notably, method of administration likely influences
the development of methamphetamine-induced neurotoxicity based on preclinical studies in
rhesus macaques that demonstrated a similar peak temperature but delayed onset when the
drug is administered orally compared to peritoneal injections (Crean et al., 2007; Crean et al.,
2006).
Methamphetamine metabolism occurs primarily in the liver through three main
processes. These include N-demethylation via cytochrome P450 2D6, aromatic hydroxylation
through cytochrome P450 2D6, and ß-hydroxylation, producing amphetamine, 4hydroxymethamphetamine, and norephedrine, respectively (Schep et al., 2010). It seems
3

unlikely that metabolites are responsible for clinical effects of the ingested drug due to the fact
that peak metabolite levels occur after approximately 12 hours, producing minimal
effects(Cruickshank and Dyer, 2009). Within one day of dosing, nearly 70% of
methamphetamine is excreted in the urine. Analysis reveals 30-50% is in the form of
methamphetamine, up to 15% as 4-hydroxymethamphetamine, and 10% as
amphetamine(Cruickshank and Dyer, 2009).
Methamphetamine is metabolized by CYP2D6 at the first step of hydroxylation and
demethylation (Dougan et al., 1987). Variants of CYP2D6 can alter responses and effects to
methamphetamine in humans. Ramamoorty et al (2001) demonstrated intrinsic clearance of
methamphetamine in 4-hydroxylation in CYPD2D6 mutant mice were 30-67 fold slower
compared to wild type. Other studies have found distributions of CYD2D6 allele and phenotype
frequency were significantly associated with susceptibility to methamphetamine dependence
(Otani et al., 2008). Reduced CYD2D6 activity is believed to be a negative risk factor for
methamphetamine dependence as well (Otani et al., 2008).

1.1.3. Clinical Implications of Methamphetamine. Methamphetamine use is responsible
for an estimated 94,000 emergency department admissions yearly with presenting symptoms
largely dependent on the dose taken(NIDA, 2011).Symptoms commonly observed by medical
personnel, particularly in high-dose patients, include hypertension, tachycardia, dyspnea,
hyperthermia, and chest pain with other presenting symptoms involving increased agitation,
altered mental status, pupil dilation, shivering, and possible seizure activity(Albertson et al.,
1999).While clinical experiments and reporting of emergency department presentations have
resulted in an improved understanding of the behavioral and medical implications of
methamphetamine-induced effects, relatively little is understood concerning long-term health
implications of acute and/or chronic methamphetamine-induced complications. These systemic
events, particularly those associated with an increased metabolic rate and cardiovascular
4

changes leading to tachycardia and hypertension, can contribute to neurotoxicity and
hyperthermia.

1.1.4 Methamphetamine and Other Non-toxic Drugs of Abuse
The neurotoxic effects of methamphetamine stem from its ability to enter the cell (highly
lipophilic structure). Other psychostimulants, such as cocaine, may produce the same euphoric
feeling (from an acute increase in dopamine), however lack the neurotoxic component because
of its inability to cross the cell membrane and induce neurotoxic consequences. In addition,
methamphetamine is believed to interact directly with sigma receptors as it binds to both
subtypes at physiologically relevant concentrations (Matsumoto, 2009). Ethanol and nicotine,
two other non-toxic drug of abuse, do not interact with sigma receptors and its effects are likely
downstream (Robson et al., 2012). Other drugs of abuse act at different systems than that of
methamphetamine. PCP, a strong hallucinogen believed to produce severe cognitive
impairments, acts primarily through NMDA receptors (Morris et al., 2005). Opioids also act via a
completely different series of cascades and receptors compared to methamphetamine (Kasai
and Ikeda, 2011).

1.2 Methamphetamine mechanism of action
The immediate effects of methamphetamine are similar to other amphetamines in which
the user experiences an increase in energy with a lessened sense of anxiety, increased
productivity and overall strong feeling of euphoria (Cadet and Krasnova, 2009; Davidson et al.,
2001). Chronic methamphetamine use results in increased anxiety, depression,
aggressiveness, psychomotor dysfunction, and as recent reports indicate, Parkinson’s like
symptoms(Cadet and Krasnova, 2009; Krasnova and Cadet, 2009).
Methamphetamine is an indirect agonist that can cause the release of newly synthesized
monoamine neurotransmitters, particularly dopamine and serotonin, and inhibit their reuptake
5

from the synapse by the dopamine transporter (DAT) and serotonin transporter (SERT) (Sulzer
et al., 2005). While the exact mechanism is unknown, it appears as though methamphetamine
causes a redistribution of dopamine and serotonin from the synaptic vesicles, through the
vesicular monoamine transporter (VMAT2), into the neuronal cytoplasm (Kish, 2008; Sulzer et
al., 2005). The acute euphoric effects of methamphetamine are a result of this immediate
increase in dopamine and serotonin. However, excess dopamine and serotonin in the cytoplasm
and synaptic cleft are believed to undergo auto-oxidation resulting in the creation of reactive
particle formation (Cadet et al., 2007; Tata et al., 2007). The free radicals formed are thought to
be a primary cause of nerve ending damage associated with methamphetamine abuse (Tata et
al., 2007). Figure 1.1 displays the molecular effects of methamphetamine on dopminergic
transmission in regions of the brain thought to be affected following methamphetamine
exposure (Kish et al. 2009).

Figure 1.1. Pharmacologic effects of methamphetamine on the dopaminergic system. Schematic diagram of
the human dopamine-rich striatum, which is made up of the caudate nucleus, putamen and ventral striatum (left), and
a striatal dopamine nerve ending (right). Methamphetamine causes dopamine release from the nerve endings.
Normally, dopamine released into the synapse is taken back up into the nerve ending by the dopamine transporter
and is transported into the synaptic vesicle by the vesicular monoamine transporter 2. Methamphetamine causes the
release of striatal dopamine from the nerve ending into the synapse. This likely involves the translocation of
dopamine from the synaptic vesicle to the neuronal cytoplasm via the vesicular monoamine transporter 2 and the
reverse transport of dopamine from the cytoplasm into the synapse via the dopamine transporter. Figure and legend
from Kish et al., 2009 and image by Lianne Friesen and Nicholas Woolridge.
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1.3 Methamphetamine neurotoxicity
The neurotoxic effects of methamphetamine have been well characterized and a number
of hypotheses have been reported for understanding the mechanisms involved in
methamphetamine-induced neurotoxicity. Some of these, seen in figure 1.2 include: reactive
oxygen species (involved in a variety of effects), hyperthermia, excitotoxicity (glutamate
release), blood brain barrier disruption, mitochondrial dysfunction, microglial activation, and
death cascades (autophagy).

1.3.1 Reactive Oxygen Species (ROS). ROS has become one of the key components
thought to lead to methamphetamine-induced neurotoxicity. Following entry into the cell via
quick diffusion or transport by the DAT/SERT, methamphetamine causes a release of
neurotransmitters from the synaptic vesicle via VMAT2(Cadet and Krasnova, 2009; Krasnova
and Cadet, 2009). Furthermore, methamphetamine causes a reduction in DAT/SERT
decreasing the reuptake of excess dopamine and serotonin from the synaptic cleft and
damages VMAT2, thereby preventing neurotransmitter storage within the cytoplasm (Krasnova
and Cadet, 2009). Subsequently, excess dopamine and serotonin undergoes auto-oxidation to
form toxic quinones with generation of superoxide radicals and hydrogen peroxide via quinone
cycling (Kita et al., 2003; Krasnova and Cadet, 2009). Formation of hydroxyl radicals through
interactions of superoxides radicals and hydrogen peroxide with transition metals lead to the
creation of oxidative stress(Kita et al., 2003). This increase in oxidative stress disrupts lipids,
proteins, mitochondrial and nuclear DNA which may play a role in methamphetamine-induced
nerve-degeneration and neuronal apoptosis(Cadet et al., 1997; Davidson et al., 2001).

1.3.2 Hyperthermia. Methamphetamine-induced hyperthermia has been shown to be an
important component of neurotoxicity. Temperature alterations can drastically change the
7

effects of methamphetamine-induced neurotoxicity. When temperature is increased,
neurotoxicity is exacerbated while a certain degree of neuroprotection can be seen when
temperature is decreased(Bowyer et al., 1994). Animal and clinical reports have indicated a
tight correlation between the lethality of methamphetamine and hyperthermia(Bowyer et al.,
1994; Davidson et al., 2001). Overall, methamphetamine-induced hyperthermia has been
shown to be correlated with nerve terminal degeneration, however is not sufficient by itself
(Davidson et al., 2001). The relationship between neurotoxicity and hyperthermia still remains
ambiguous; however dopamine and serotonin appear to play a vital role.
Methamphetamine has been reported to cause an increase in the release of dopamine
and serotonin in various regions of the brain potentially involved in temperature regulation
(Phelps et al., 2010). Dopamine and serotonin are thought to be directly involved in temperature
regulation within the CNS(Cannon and Nedergaard, 2004; Salmi, 1998; Salmi and Ahlenius,
1998; Salmi et al., 1993) and may play roles in the hyperthermic effects of methamphetamine
(Bowyer et al., 1994; Rusyniak et al., 2008). Since thermoregulation within the hypothalamus is
thought to be primarily controlled by dopamine and serotonin (Mallick et al., 2002), the effects of
methamphetamine on these neurotransmitter systems are of significant importance.

1.3.2.1 Dopamine: The dopaminergic system is believed to be the primary site for
methamphetamine and subsequent research dedicated to understanding methamphetamineinduced hyperthermia have focused largely on dopamine. Following administration,
methamphetamine can readily enter the cell and facilitate the increased release of dopamine
while preventing the reuptake (Cadet and Krasnova, 2009; Davidson et al., 2001). Studies have
shown dopamine receptor activation is a necessary component for methamphetamine-induced
hyperthermia (Funahashi et al., 1990; Albers and Sonsalla et al., 1995; He et al., 2004;
Broening et al., 2005). LaVoie and Hastings showed that maintaining a low ambient
temperature, thus preventing hyperthermia, can prevent increases in dopamine oxidation
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products(LaVoie and Hastings, 1999). One of the most significant findings in this area was from
Bowyer et al., which demonstrated the degree of hyperthermia following methamphetamine
administration correlated with subsequent depletions in striatal dopamine and lethality and was
potentiated by increasing environmental temperatures. In addition, this study demonstrated cold
environments that reduce core body temperature can significantly decrease striatal extracellular
dopamine concentrations following methamphetamine administration (Bowyer et al., 1994).

1.3.2.2 Serotonin: Similar to dopamine, serotonin has a distinctive role in
thermoregulation and subsequent neurotoxicity. Serotonergic pathways have been directly
implicated in the central control of most forms of thermogenesis (Rothwell, 1994). Previous data
have shown that changes in neuronal serotonin levels correlate with changes in brain and core
body temperatures (Salmi and Ahlenius, 1998; Schwartz et al., 1995). In addition, serotonin
regulates skin blood flow, which is a major mechanism in thermoregulation (Maurer-Spurej,
2005).Methamphetamine facilitates serotonin release in the nerve terminal (Ago et al., 2006;
Kuczenski et al., 1995)which can lead to increases in body temperature (Fukumura et al., 1998;
Numachi et al., 2007). Numachi et al. demonstrated that while methamphetamine is likely to
exert its hyperthermic effects primarily through the DAT, the SERT may have a compensatory
role in the absence of the DAT. Other reports have suggested directly or indirectly blocking the
actions of released serotonin on the central neuronal pathways involved in the temperature
regulation can prevent temperature elevation in addition to serotonergeric neurotoxicity (Azzaro
and Rutledge, 1973; Ginawi et al., 2005).

1.3.3 Excitotoxicity (glutamate release). Methamphetamine administration can lead to
increased release of glutamate (Nash and Yamamoto, 1992).Known as excitotoxicity, NMDA
receptors become activated leading to another source of reactive species(Nash and Yamamoto,
1992). The underlying effects seen as a result of glutamate release stems from nitric oxide and
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nitric oxide synthase. Increases in glutamate leads to a subsequent increase in intracellular
calcium levels which activates various kinases, lipases, and proteases ultimately ending in free
radical generation and DNA damage (Quinton and Yamamoto, 2006). The calcium influx
induced via NMDA activation has been reported to be correlated with an increase in nitric oxide
synthase activation, which further leads to reactive particle formation (Schmidt et al., 1996). It is
also important to point out excess intracellular calcium release may be in and of itself sufficient
to increase reactive particle formation (Kahlert et al., 2005).

1.3.4 Mitochondrial Dysfunction. Due to the lipophilicity of methamphetamine, it can
readily diffuse into the mitochondria and subsequently be retained (Davidson et al., 2001). It has
now become apparent that methamphetamine affects the electrochemical gradient formed from
the electron transport chain (ETC) resulting in decreased ATP synthesis, ultimately ending in a
decreased energy state (Krasnova and Cadet, 2009; Quinton and Yamamoto, 2006). In addition
to the decreased energy output, the effects methamphetamine has on the mitochondria can be
detrimental when it comes to the increased ROS production(effects on lipids and DNA) seen
following administration (Krasnova and Cadet, 2009). The disruptive effects on the mitochondria
can further alter calcium storage. Methamphetamine leads to a release of stored calcium
through the permeability transition pore (PTP) which can in turn result in activation of
programmed cell death proteases and caspases (Davidson et al., 2001).The mitochondria,
which has been linked to the necrotic and apoptotic cell death pathways seen with several of the
known neurodegenerative diseases (Davidson et al., 2001), can trigger a series of cellular
events ending with neuronal death. Methamphetamine has been reported to increase proapoptotic proteins (Bax, Bad, and Bid) while decreasing anti-apoptotic proteins (Bcl-2 and BclXl) resulting in the release of cytochrome c and apoptosis inducing factor (AIF) into the cytosol
(Krasnova and Cadet, 2009).
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1.3.5 Microglial Reactions. Under normal physiologically conditions, microglial cells act
as the macrophages within the brain and spinal cord. A dose-dependent microglial activation
was reported following methamphetamine administration (Thomas et al., 2004) indicating the
systems response following exposure. Methamphetamine-induced neurotoxicity was shown to
be attenuated following the treatment with a non-steroidal anti-inflammatory drug (Asanuma et
al., 2003). A variety of evidence suggests that once activated, microglial cells release an
abundance of cytokines, reactive oxygen and nitrogen particles, and prostaglandins believed to
be involved in nerve terminal damage (Krasnova and Cadet, 2009). Specifically,
methamphetamine was shown to initiate a microglial response in regions of the brain that
undergo neuronal degeneration (Krasnova and Cadet, 2009). While protection from excess
microglial activation is not sufficient to prevent against methamphetamine-induced neurotoxicity,
it appears that activated microglial cells exacerbate methamphetamine-induced neurotoxicity
similarly to hyperthermia (Krasnova and Cadet, 2009). Sustained increases in intracellular
calcium levels have also been shown to be important to the induction of the inflammatory
response, specifically microglia activation (Hoffmann et al., 2003).

1.3.7 Death Cascades (autophagy). As previous reports have indicated, neurotoxic
doses of methamphetamine can induce autophagy both in vivo and in vitro (Krasnova and
Cadet, 2009). Cytoplasmic vacuoles which resemble autophagic molecules have been shown in
striatal dopaminergic neurons and gabanergic neurons following methamphetamine exposure
(Krasnova and Cadet, 2009).Based on evidence of dopamine’s role in methamphetamineinduced dysfunction of the ubiquitin-proteasome system as well as formation of cytoplasmic
vacuoles, it appears as though dopamine is the primary factor in which methamphetamine can
induce autophagy.
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Figure 1.2
2 Neurotoxic effects of m
methamphetamine. Methamphetamine (MA) is believed to enter the cell
through the dopamine and serotonin transporter. Once into the cell, methamphetamine can cause a series of cellular
events including: dopamine
opamine and serotonin release and subsequent auto
auto-oxidation resulting
g in reactive particle
formation, activation of microglia cells, mitrochondrial dysfunction and release of calcium through the post transtrans
membrane pore, NMDA activation from glutamate release, increase in body temperature, and ultimately nerve
n
terminal degeneration. MA=methamphetamine,
ethamphetamine, DAT=dopamine transporter, SERT=serotonin transporter,
DA=dopamine, 5-HT=serotonin,
HT=serotonin, Glut=glutamate, NTD=nerve terminal degeneration.

1.4 Interactions between methamphetamine and sigma receptors
In addition to interacting with various neurotransmitter systems
systems(Fleckenstein
(Fleckenstein et al.,
2000),, methamphetamine is thought to interact with sigma receptors (Itzhak,, 1993; Nguyen et
al., 2005) (Table 1.1).
Table 1.1.
.1.Sigma binding affinity of methamphetamine.

Sigma-1 Ki (µM)

12

Sigma-2
Sigma Ki (µM)

Methamphetamine

2± 0.2

47 ± 10

Recent evidence has shown that methamphetamine produces some of its physiological
and behavioral effects through sigma receptors (Nguyen et al., 2005), suggesting a potential
site for pharmacological intervention. Specifically, sigma receptors are thought to have a role in
the behavioral and neurotoxic effects of methamphetamine (Matsumoto et al., 2008). Sigma
receptors are found on monoaminergic neurons (Bastianetto et al., 1995; Booth and
Baldessarini, 1991; Gundlach et al., 1986) and modulate the release of neurotransmitters such
as dopamine and serotonin(Matsumoto et al., 2008; Salmi and Ahlenius, 1998; Schwartz et al.,
1995). In addition, sigma receptor ligands can modulate thermoregulation (Rawls et al., 2002),
likely through an interaction with thermosensitive neurons in the hypothalamus (Bouchard and
Quirion, 1997; Mei and Pasternak, 2001).

1.4.1 Gender Differences and Implications for Methamphetamine and Sigma Receptors
Previous reports have suggested woman maybe more likely to use methamphetamine
than males and methamphetamine has the highest rate of females currently being treated for
addiction (Dluzen et al., 2007). No significant differences in direct pharmacokinetic comparisons
have been reported between males and females however gastrointestinal transit time is greater
in the luteal phase which would suggest greater absorption in females (Lynch et al., 2002).
Other studies have shown amphetamine-stimulated dopamine release was higher in men than
woman (Munro et al., 2006). Additionally, and as other reports have shown, woman may have
less neurotoxicity compared to men due to the neuroprotective effects of estrogen (Dluzen et
al., 2007). Protective effects against amphetamines have been directly correlated with estrogen
levels (Justice et al., 1999) and treatment with an estradiol patch provided protection against the
effects of amphetamine (Justice et al., 2000). Lastly females appear more likely than males to
receive treatment and acknowledge dependence (Dluzen et al., 2007).
13

The irony of gender differences in methamphetamine abuse lies in the fact that despite woman
are more dependent on and vulnerable to methamphetamine use, they appear more protected
against the toxic effects of methamphetamine (Dluzen et al., 2007).
Previous studies have demonstrated neuroactive steroids such as progesterone may be
an endogenous ligand for the sigma receptor (Matsumoto et al., 2009). Additionally, a more
recent report suggested the sigma-2 receptor binding site as progesterone receptor membrane
component 1 (PGMRC1) and overexpression and knockdown of the PGRMC1 protein resulted
in an increase (overexpression) and a decrease (knockdown) in binding of a sigma-2 selective
radioligand (Xu et al., 2011). Due to the interactions of progesterone with the sigma receptor,
the majority of sigma studies utilize male mice. While the effects have not been directly
compared with both male and female animals, it is likely that different results would be observed
based on gender.

1.5 Sigma receptors
Sigma receptors are unique proteins which are distinct from other known receptors and
consist of at least two subtypes, sigma-1 and sigma-2(Guitart et al., 2004; Matsumoto et al.,
2003; Su and Hayashi, 2003). They are distributed in the brain and peripheral organs(Itzhak,
1993; Walker et al., 1992). Of the two subtypes, sigma-1 receptors are localized intercellularly
(Hayashi et al., 2000; Hayashi and Su, 2003) and have been cloned in several species (Mei and
Pasternak, 2001; Prasad et al., 1998). Sigma-1 receptors have important roles in the modulation
of several neurotransmitters by affecting intracellular second messenger systems, particularly
calcium mobilization (Hayashi et al., 2000; Hayashi and Su, 2003). In addition, because of the
chaperone like characteristics of sigma-1 receptors, they are believed to partake in proteinprotein interactions and undergo translocation between various cellular compartments (Hayashi
and Su, 2007). Sigma-2 receptors, on the other hand, have not been cloned and at 18-22 kDa,
are smaller than sigma-1 receptors (Hellewell et al., 1994). They are believed to regulate
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calcium release from stores within the endoplasmic reticulum (Bowen et al., 1995; Vilner and
Bowen, 2000) and are implicated in the regulation of cell proliferation and cell viability (Vilner
and Bowen, 1993; Vilner et al., 1995b). As with the sigma-1 receptor, sigma-2 receptors are
widely distributed throughout the cell including the mitochondria, endoplasmic reticulum,
lysosome, and plasma membrane (Zeng et al., 2007).

1.5.1 Sigma Receptors in Post Mortem Brains
Previous studies have shown [3H]-haloperidol, a high affinity sigma receptor compound,
in the presence of 50 nM spiperone binds to a single and saturable class of receptors in the
human brain (Weissman et al., 1988). In addition to haloperidol ,d-3-PPP was found to have
high affinity for the sigma receptor binding site in post-mortem studies, whereas other potent
dopaminergic drugs (apomorphine, d-butaclamol) are relatively less potent at sigma receptors.
The cerebellum was also found to have a high density of sigma receptors in the human brain as
haloperidol and DTG were found to bind to sigma receptors in this region (Su et al., 1982; Tam,
1983, Gundlach et al. 1986). In post mortem schizophrenic brains, nemonapride-labeled sigma
receptor binding was decreased compared to normal controls (Helmeste et al., 1996). Other
studies evaluated memantine and amantadine for their ability to compete with (+)-pentazocine
in homogenates of post-mortem human frontal cortex. Memantine likely does not interact with
sigma receptors; however Amantadine, at therapeutic concentrations, probably binds both to the
sigma site and to the phencyclidine (PCP) binding site of the N-methyl-D-aspartate (NMDA)
receptor (Kornhuber et al., 1993).

1.5.2 Sigma Receptor Knockout/Knockdown Studies
Several sigma receptor knockout studies have been done since the cloning and
sequencing of the sigma-1 receptor. Despite the broad expression pattern found for the sigma-1
gene, homozygous mutant mice are viable, fertile and did not display any obvious phenotype,
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when compared to control litter mates (Langa et al., 2003). However, a significant decrease in
the hypermotility response was found in knockout mice upon challenge with (+)SKF-10 047, in
agreement with the involvement of sigma 1-receptors in the induction of psychostimulant actions
(Langa et al., 2003). Furthermore, sigma-2 receptors activity does not appear to be affected
from the knockout of the sigma-1 receptor. Other studies concluded sigma-1 knockout mutants
displayed an increase in immobility time using the forced swimming test, but demonstrated
normal anxiety-like behavior in the elevated plus-maze and light/dark box tests and normal
locomotor activity (Sabino et al., 2009). Formalin-induced pain was also shown to be reduced by
approximately 55% in sigma-1 receptor knockout mice in comparison to wild-type animals
(Cendan et al., 2005). Lastly, studies looking at the effects of methamphetamine in sigma-1
knockout mice indicated methamphetamine still produces its effects, potential indicating a
compensatory role for the sigma-2 receptor (Fontanilla et al., 2009).
A couple of studies have explored knockdown studies to further evaluate the effects of
sigma-1 receptors. Studies that have used sequence-specific antisense oligonucleotides have
demonstrated a role for sigma-1 receptors in the actions of drugs of abuse such as cocaine and
methamphetamine (Matsumoto et al., 2002; Nguyen et al., 2005). Specifically, antisense
oligodeoxynucleotide against sigma-1 receptors were found to attenuate the convulsive and
locomotor stimulant effects of cocaine (Matsumoto et al., 2002). In addition, mice that were
administered an antisense oligodeoxynucleotide to down-regulate the sigma-1 receptor were
found to display reduced locomotor stimulatory response to methamphetamine when compared
to control mice receiving mismatch oligonucleotides (Nguyen et al., 2005).

1.6 Sigma receptor ligands

16

CM156-(3-(4-(4-cyclohexylpiperazin-1-yl)butyl)benzo[d] thiazole-2(3H)-thione)

AZ66- (3-(4-(4-cyclohexylpiperazin-1-yl)pentyl)-6-flourobenzo[d]thiazol-2(3H)-one)
Two compounds were used throughout the studies presented herein, CM156(3-(4-(4cyclohexylpiperazin-1- yl)butyl)benzo[d] thiazole-2(3H)-thione) and AZ66(3-(4-(4cyclohexylpiperazin-1-yl)pentyl)-6-flourobenzo[d]thiazol-2(3H)-one). CM156 and AZ66were
synthesized to have high affinity and selectivity for sigma receptors over other non-sigma sites
(Maeda et al., 2002; Seminerio et al., 2011b; Xu et al., 2010). CM156 is a previously studied
compound (Kaushal et al., 2009; Kaushal et al., 2011; Xu et al., 2010; Xu et al., 2012) that was
optimized for metabolic stability and led to the development of our lead analog, AZ66.The
affinities of CM156 and AZ66 for sigma-1 and sigma-2 receptors, as well as other receptors,
transporters, ion channels and binding sites are listed in Table 1.2.

1.7.1 Receptor Binding Assays: The radioligand binding assays were preformed in rat
brain homogenates using methods previously described in detail (Matsumoto et al., 1995;
Matsumoto et al., 2008). Briefly, sigma-1 receptors were labeled with 5 nM [3H](+)-pentazocine
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and sigma-2 receptors were labeled with 3 nM [3H]di-o-tolylguanidine (DTG)in the presence of
300 nM (+)-pentazocine to block sigma-1 receptors. Nonspecific binding was determined in the
presence of 10 µM haloperidol. All of the assays were terminated with the addition of ice-cold
buffer and rapid vacuum filtration over glass fiber filters. To further evaluate CM156 and AZ66
binding profile, the compounds was subject to NOVAScreen (Caliper Life Sciences, Hanover,
MD) at targets not previously tested in our lab. Further details of each assay condition can be
accessed through their website at www.caliperls.com.
Table 1.2. Binding affinity of CM156 and AZ66 for sigma receptors and non-sigma receptor sites
Binding Site

Radioligand

Nonspecific binding

Tissue or cell

Sigma Receptors:

Ki
CM156

AZ66

Sigma-1
5 nM [3H](+)-pentazocine
Sigma-2
3 nM [3H]di-o-tolylguanidine
Monoamine Transporters:

10 μM haloperidol
10 μM haloperidol

Rat brain
Rat brain

1.3±0.4
0.6±0.1

1.20±0.2
0.31±0.1

Dopamine
0.5 nM [3H]WIN 35,428
Serotonin
0.2 nM [3H]paroxetine
Norepinephrine
0.5 nM [3H]nisoxetine
Neurotransmitter Related:

50 μM cocaine
1.5 μM imipramine
4 μM desipramine

Rat striatum
Rat brainstem
Rat cerebral cortex

1175 ±100
1402±152
>10,000

872±122
612±44
>10,000

1 µM NECA
1 µM Phentolamine
mesylate
1 µM Phentolamine
mesylate
3 µM alprenolol

Bovine striatum
Rat forebrain

>10,000
>100

>10,000
>100

Rat cortex

>100

>100

>10,000

>10,000

>10,000

>10,000

>10,000

>10,000

>100
>10,000

>100
>10,000

Adenosine
Adrenergic,
alpha1
Adrenergic,
alpha2
Adrenergic, beta1

4.0 nM [3H]NECA
0.3 nM [3H]7-MeOxyPrazosin
1 Nm [3H]RX 821002

Cannabinoid, CB1

0.04 nM [125I]()iodocyanopindolol
0.5 nM[3H]CP 55940

Cannabinoid, CB2

0.5 nM[3H]CP 55940

1 µM HU-210

Dopamine D4.2
GABA A, agonist
site
GABA A, BDZ
alpha 1
GABA-B
Glutamate, AMPA
Glutamate, kainite
Glutamate, NMDA
agonist
Glutamate, NMDA
glycine
Glutamate,
NMDA/PCP
Glutamate,
mGluR1
Glutamate,
mGluR5
Glycine,strychnine

5 nM [3H](-)-sulpiride
5 nM [3H]GABA

1 µM haloperidol
1 µM GABA

Human
Neuroepithelioma
Human recombinant
HEK293 cells
Human recombinant
CHO cells
Rat brain
Bovine cerebellum

1 nM [3H]flunitrazepam

0.5 µM flumazenil

Bovine cortex

>10,000

>10,000

1 nM [3H]CGP 54626A
5 nM [3H]AMPA
10 nM [3H]kainic acid
2 nM[3H]CGP 39653

100 µM baclofen
100 µM AMPA
10 µM kainic acid
300 µMNMDA

Rat cerebral cortex
Rat forebrain
Rat forebrain
Rat forebrain

>10,000
>10,000
>10,000
>10,000

>10,000
>10,000
>10,000
>10,000

4 nM[3H]MDL-105,519

3 µMMDL-105,519

Rat cortex/hippoc

>10,000

>10,000

10 nM[3H]TCP
5 nM [3H]TCP
20 nM [3H]quisqualic acid

100 µM (+)-MK801
10 µM cyclazocine
1 mM L-glutamate

Rat forebrain
Rat brain
Rat cerebellum

>10,000>10
,000
>10,000

>10,000>
10,000
>10,000

10 nM [3H]MPEP

10 µM MPEP

Rat brain

>10,000

>10,000

16 nM [3H]strychnine

100 µM strychnine
nitrate

Rat spinal cord

>10,000

>10,000

1 µM HU-210
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Histamine H1

2 nM [3H]Pyrilamine
125

Histamine H2
Histamine H3

0.1 nM [ I]aminopotentidine
0.2 nM [3H]N-a-MeHistamine

Muscarinic,
central
Muscarinic,
peripheral
Muscarinic M1

0.15 nM [3H]QNB
3

10 µM Triprolidine
3 µM tiotidine
100 nM R(-)aMethylhistamine
0.1 µM atropine

Bovine cerebellar
membranes
Guinea pig striatum
Rat forebrain

>100

>100

>100
>100

>100
>100

Rat cerebral cortex

>100

>100

0.3 nM [ H]QNB

0.1 µM atropine

Guinea pig bladder

>100

>100

0.5 nM [3H]N-methyl
scopolamine

1 µM (-)scopolamine

Human recombinant
CHO cells

>100

>100

Muscarinic M2

0.5 nM [3H]N-methyl
scopolamine

1 µM
methylscopolamine

Human recombinant
CHO cells

>100

>100

Nicotinic, muscle
Nicotinic,
neuronal
Opioid, Kappa 1

1 nM[125I]α-bungarotoxin
0.05 nM [3H]epibatidine

10 µMnicotine
20 nM epibatidine

Human TE671 cells
Human SK-N-F1 cells

>10,000
>10,000

>10,000
>10,000

0.75 nM [3H]U-69593

1 µM U69593

>10,000

>10,000

1 µM Naloxone

Guinea pig
cerebellum
Rat forebrain

>10,000

>10,000

1 µM angiotensin II

Human KAN-TS cells

>10,000

>10,000

0.05 µM angiotensin II

Bovine cerebellum

>10,000

>10,000

100 nM bradykinin TFA
1 µM CCK-8

Guinea pig ileum
Mouse pancreas

>10,000
>10,000

>10,000
>10,000

1 µM CCK-8

Mouse forebrain

>10,000

>10,000

1 µM Tyr -oCRF

Rat cerebral cortex

>10,000

>10,000

0.1 µM endothelin-1
0.1 µM endothelin-1
10 nM 17-estadiol
100 nM galanin
(porcine)
10 µM triamcinolone
1 µM substance P
1 µM neurokinin A

Human neuroblastoma
Human astrocytoma
Human breast cancer
Rat brain

>10,000
>10,000
>10,000
>10,000

>10,000
>10,000
>10,000
>10,000

>10,000
>10,000
>10,000

>10,000
>10,000
>10,000

>10,000

>10,000

Opioid, Mu

3

1 nM [ H]DAMGO

Hormone, peptide, steroid receptors:
Angiotensin II,
0.06 nM [125I](Sar1AT1
Ile8)angiotensin
Angiotensin II,
0.1 nM [125I]Tyr4-angiotensin
AT2
II
Bradykinin, BK2
0.2 nM [3H]bradykinin
Cholecystokinin,
0.02 nM [125I]CCK-8
CCKA
Cholecystokinin,
0.02 nM [125I]CCK-8
CCKB
CRF, non0.1 nM [125I]Tyr0-oCRF
selective
Endothelin, ETA
0.033 nM [125I]endothelin-1
Endothelin, ETB
0.025 nM [125I]endothelin-1
Estrogen
0.1 nM [125I]3,7-estradiol
Galanin, non0.07 nM [125I]galanin
selective
Glucocorticoid
1 nM[3H]dexamethasone
Neurokinin, NK1
1.4 nM [3H]substance P
Neurokinin, NK2
0.1 nM [125I]neurokinin A
Neurokinin, NK3
(NKB)
Oxytocin
Testosterone,
cytosolic
TRH
VIP, non-selective
Vasopressin 1

Ion channels:
Calcium, type L
(Benzothiazepine
Site)
Calcium, type L
(Dihydropyridine
Site)
Calcium, type N
Potassium, ATPsensitive
Potassium, Ca2+
act VI
Sodium , Site 2

0

0.1 nM [125I]eledoisin

1 µM eledoisin

Human recombinant
Rat submaxillary gland
Human recombinant
CHO cells
Rat cerebral cortex

1 nM [3H]oxytocin
0.5 nM [3H]methyltrienolone

1 µM oxytocin
0.7 µM methyltrienolone

Rat uterus
Human LnCAP cells

>10,000
>10,000

>10,000
>10,000

2 nM [3H](3MeHis2)TRH
0.05 nM [125I]VIP
0.5 nM [3H]phenylalanyl3,4,5-v

10 µM TRH
1 µM VIP
1 µM Arg8-vasopressin

Rat forebrain
Rat forebrain
Rat liver

>10,000
>10,000
>10,000

>10,000
>10,000
>10,000

5 nM [3H]Diltiazem, cis(+)

10 µM Diltiazem

Rat cerebral cortex

>100

>100

0.2 nM [3H]Nitrendipine

1 µM Nifedipine

Rat cerebral cortex

>10,000

>10,000

0.01 nM [125I]ω-conotoxin
GVIA
0.2 nM [3H]glibenclamide

0.1 µM ω-conotoxin
GVIA
0.1 µM glibenclamide

Rat cerebral cortex

>10,000

>10,000

Rat cerebral cortex

>10,000

>10,000

100 nM apamin

Rat forebrain

>10,000

>10,000

1 mM Aconitine

Rat forbrain

>100

>100

125

0.05 nM [

I]apamin

2 nM [3H]Batrachotoxin
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Enzymes and other miscellaneous:
Acetylcholine
0.3 mM
esterase
[3H]acethylthiocholine
Choline
0.2 nM [14C]acetyl coenzyme
acetyltransferase
Glutamic acid
4 µM [14C]L-glutamic acid
decarboxylase
0.48 nM [3H]leukotriene B4
Leukotriene, LTB4
(BLT)
Leukotriene, LTD4 0.2 nM [3H]leukotriene D4
(CysLT1)
MAO-A oxidase,
50 µM [14C]5-HT
peripheral
MAO-B oxidase,
10 µM [14C]phenylethylamine
peripheral
Nitric oxide, NOS
5 nM [3H]NOARG
Platelet activating
1.7 nM [3H]hexadecyl-acetylfactor
PAF
Thromboxane,
2 nM [3H]SQ 29,548
TXA2

100 µMphysostigmine

Human recombinant

>100

>100

0.1 µM Ro 41-1049

Rat cerebral cortex

>10,000

>10,000

100 µMaminooxy acetic
acid
500 nM leukotriene B4

Rat striatum

>10,000

>10,000

Guinea pig spleen

>10,000

>10,000

1 µM leukotriene D4

Guinea pig lung

>10,000

>10,000

1 µMRo 41-1049

Rat liver mitochondria

>10,000

>10,000

10 µMRo 16-6491

Rat liver mitochondria

>10,000

>10,000

100 µM NOARG
1 µM C16-PAF

Rat brain
Rabbit platelets

>10,000
>10,000

>10,000
>10,000

10 µM pinanethromboxane

Human platelets

>10,000

>10,000

Affinities (Ki in nM) were determined in tissue or cell homogenates. The values in this table represent the mean +
S.E.M. from replicate assays. Values of >10,000 signify that there was less than 30% displacement of the radioligand
at that concentration. AMPA=alpha-amino-3-hydroxy-5-methyl-4- isoxazole-propionic acid; CCK=cholecystokinin;
CGP 39653=2-amino-4-propyl-5-phosphono-3-pentenoic acid; CGP 54626A=cyclohexylmethyl-[(2S)-3-[[(1S)-1-(3,4dichlorophenyl)ethyl]amino]-2-hydroxypropyl]phosphinic acid; CP 55,940=2-[(1R,2R,5R)-5-hydroxy-2-(3hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol; CRF=corticotrophin releasing factor; DAMGO=(2S)-2-[[2[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]-methylamino]-N-(2hydroxyethyl)-3-phenylpropanamide; GABA=γ-aminobutyric acid; GVIA=(3-[125I]Iodotyrosyl22)omega-conotoxic; 5HT=serotonin; HU-210=(6aR,10aR)- 9-(hydroxymethyl)- 6,6-dimethyl- 3-(2-methyloctan-2-yl)- 6a,7,10,10atetrahydrobenzo [c]chromen- 1-ol; MAO=monoamine oxidase; MDL-105,519=(E)-4,6-dichloro-3-(2-phenyl-2carboxyethenyl)indole-2-carboxylic acid; MK801=(5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten5,10-imine hydrogen maleate dizocilpine hydrogen maleate; MPEP=2-methyl-6-(phenylethynyl)pyridine; NECA=5’-NG
ethylcarboxamidoadenosine; NMDA=(2R)-2-(methylamino)butanedioic acid; NOARG=L-N -nitro-arginine;
PAF=platelet activating factor; PCP=phencyclidine; QNB=quinuclidinyl benzilate; Ro 16-6491=N-(2-aminoethyl)-4chlorobenzamide; Ro 41,1049=N-(2-aminoethyl)-5-(3-fluorophenyl)-4-thiazolecarboxamide; Rx 821002=2-(2,3dihydro-2-methoxy-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole; SQ 29,548=[1S-[1α,2α(Z),3α,4α]]-7-[3-[[2[(phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]hept-2- yl]-5-heptenoic acid; TCP=1-(1-(2Thienyl)cyclohexyl)piperidine; TFA=trifluoroacetic acid; TRH=thyrotropin releasing hormone; U-69593=(+)-(5α,7α,8β)N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-benzeneacetamide; VIP=vasoactive intestinal peptide.

1.7 In vivo studies
All of the in vivo studies performed were done so using male Swiss Webster mice. The
mice were housed in groups of 4-6 with a 12:12-h light/dark cycle and ad libitum food and water.
Each cage was made from polysulfone and provided 542 cm2of floor space (Tecniplast,
Philadelphia, PA), which was covered with corn cob bedding and packing material (ULINE,
Waukegan, IL). The mice were acclimated for one week before being used in any experiment
and they were randomly assigned to their treatment group according to the study.
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Previous studies have demonstrated the usefulness of Swiss Webster mice in studying
the effects of methamphetamine and sigma receptors (Ali and Itzhak, 1998; Callahan et al.,
1998; Itzhak and Ali, 1996; Matsumoto et al., 2008; Nguyen et al., 2005). The choice to use
male mice rather than female is based on the varying hormones in female mice and its potential
to cause effects (either positive or negative) in our studies (Kosaka et al., 1988).

1.8 Summary/Objectives
Methamphetamine has detrimental effects on a wide array of neurological functions and
has quickly become an international public health concern. With the absence of a proven
pharmacological agent to counteract methamphetamine-induced complications, the
development of a therapeutic treatment is essential. Methamphetamine has been shown to
bind to sigma receptors at physiologically relevant concentrations, and sigma receptors have
emerged as viable therapeutic targets. In particular, CM156, a selective sigma receptor ligand,
displayed high nanomolar affinity at both sigma-1 and sigma-2 receptors while providing in-vivo
protective effects against methamphetamine-induced neurotoxicity and locomotor hyperactivity.
However, an exceedingly short half-life due to poor metabolic stability has deemed the
compound inadequate for pursuing future drug studies in humans. The hypothesis of this
work is that CM156 can be structurally optimized to a more metabolically stable
compound while demonstrating neuroprotective properties against the neurotoxic,
behavioral, and cognitive effects of methamphetamine. Accordingly, CM156 analogs have
been synthesized by our collaborators at the University of Mississippi, under the supervision of
Dr. Christopher McCurdy. To test our hypothesis, the project has three specific aims:
1.To confirm high affinity and relative selectivity of novel CM156 analogs for sigma
receptors in addition to increased metabolic stability (Chapter 2).Structural modifications
were made with the notion that there will be no significant change in binding affinity but display
increased metabolic stability. Affinities will be determined at both sigma-1 and sigma-2
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receptors using radioligand binding assays. Furthermore, following the identification of a lead
compound, a comprehensive binding profile, via Novascreen, will be completed and metabolic
stability studies will be performed to determine the lead compound’s half life compared to
CM156.
2.To demonstrate protective effects of novel CM156 analogs in-vivo againstthe
behavioral and neurotoxic effects of methamphetamine (Chapter 3 & 4). Mice will be
pretreated with the lead analog and its ability to attenuate methamphetamine-induced stimulant
(locomotor and behavioral sensitization) and neurotoxic (dopaminergic and serotonergic
neurotoxicity and hyperthermia) effects will be evaluated.
3. To demonstrate protective effects of novel CM156 analogs in-vivo againstthe cognitive
effects of methamphetamine (Chapter 5). Mice will be pretreated with the lead analog and its
ability to attenuate methamphetamine-induced cognitive impairments will be evaluated.
The overall goal of this study is to develop a lead sigma receptor ligand that can be
pursued as a first- line treatment for methamphetamine-induced complications. It is anticipated
that if the specific structural enhancements made to CM156 yield similar pharmacological
profiles with increased metabolic stability, future pharmacotherapies are likely to be developed.

1.9 Contributions
Compounds CM156 and AZ66 were synthesized by Dr. Christophe Mésangeau and
Ahmed Abdelazeem in Dr. Christopher R. McCurdy’s lab at University of Mississippi.
The radioligand binding studies for CM156 and AZ66 were performed by Dr. Jamaluddin
Shaikh and Michael Seminerio at the University of Mississippi and West Virginia University. The
NOVAScreen for both compounds were performed by Calipers Life Sciences (Hanover, MD).
The National Institute on Drug Abuse (NIDA) very generously supported the Novascreen costs
in their medications development program.
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CHAPTER 2
OPTIMIZATION OF CM156
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2.1 Introduction
There are no effective pharmacological agents to aid in the treatment of
methamphetamine-induced complications. This is problematic because over 12 million
Americans have used methamphetamine at least once in their life (Services, 2007) and
methamphetamine ranks second worldwide only to cannabis as the most extensively abused
drug (Krasanova and Cadet, 2009). In 2005, an estimated 20-40 billion dollars was spent on
methamphetamine-related complications stemming from addiction, premature death, and
psychological treatment (Nicosia et al., 2008). The development of a novel pharmacological
agent to treat the effects of methamphetamine would results in substantial health and economic
benefits.
Previous work has suggested methamphetamine may produce some of its physiological
and behavioral effects through sigma receptors (Nguyen et al., 2005). Sigma receptors are
found on monoaminergic neurons (Bastianetto et al., 1995; Booth et al., 1991) and
methamphetamine binds to these receptorsat physiologically relevant concentrations (Itzhak et
al., 2005).Two subtypes of sigma receptors have been characterized, designated sigma-1 and
sigma-2. The subtypes differ in their cellular and anatomical distribution in addition to their
function (Guitart et al., 2004). Sigma-1 receptors have been cloned with high homology and
identity in different species (Guitart et al., 2004) and are through to have a role in calcium
regulation at the endoplasmic reticulum (ER)-mitochondrion interface (Hayashi et al., 2007).
Sigma-2 receptors have yet to be cloned but have been linked to cell cycle function and
apoptosis (Crawford and Bowen, 2002; Matsumoto et al., 2007).
The overall objective of this study is to optimize a novel sigma receptor ligand with
protective effects against methamphetamine by enhancing its metabolic stability. Through the
administration of a selective sigma receptor ligand, we hope to mitigate neurologic
complications induced by methamphetamine. In an earlier study, we reported that a high affinity
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and selective sigma receptor ligand, CM156 (3-(4-(4-cyclohexylpiperazin-1yl)butyl)benzo[d]thiazole-2(3H)-thione), provided protective effects following methamphetamine
exposure (Kaushal et al., 2011). However, due to poor metabolic stability, CM156 was deemed
inadequate for future drug development studies in humans. In an effort to increase metabolic
stability while maintaining protective effects through sigma receptors, a series of CM156
analogs were synthesized. Two primary structural moieties, cyclohexylpiperazine and
benzo[d]thiazole, have been reported to be important for sigma receptor selectivity (Berardi et
al., 2004). Additionally, a four methylene spacer between the piperazine and heterocyclic
system increases sigma-2 affinity (Mesangeau et al., 2008).Therefore, analogs were designed
to maintain these vital components. Methyl groups were added to prevent N-dealkylation while a
fluoride group, previously shown to enhance sigma selectivity, was included to increase the
electronegativity of the structure. Overall, 30 compounds were designed and synthesized
toincorporate modifications that provide steric hindrance, bulkiness, and stability which may
prevent early metabolic breakdown. In addition, in vitro and in vivo metabolism studies were
conducted to determine the half life of compounds that demonstrated high sigma receptor
binding affinity.

2.2 Materials and Methods
2.2.1 Competition Binding Assays. To determine the binding affinity for each of the
CM156 analogs, radioligand binding studies were performed. The radioligand binding assays
were preformed in rat brain homogenates using methods previously described in detail
(Matsumoto et al., 1995; Matsumoto et al., 2008). Briefly, sigma-1 receptors were labeled with 5
nM [3H](+)-pentazocine and sigma-2 receptors were labeled with 3 nM [3H]di-o-tolylguanidine
(DTG)in the presence of 300 nM (+)-pentazocine to block sigma-1 receptors. Nonspecific
binding was determined in the presence of 10 µM haloperidol. All of the assays were terminated
with the addition of ice-cold buffer and rapid vacuum filtration over glass fiber filters.
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2.2.2 In Vitro Metabolism Studies. In order to confirm structural modifications to CM156
resulted in increased metabolic stability, in vitro metabolism studies were conducted. Analogs
were evaluated in liver microsomes prepared from rat using standard procedures. Analogs (5
μM) were incubated at 37°C in 50 mM potassium phosphate buffer (pH 7.4), 3 mM MgCl2, and 1
mM EDTA (pH 7.4), in the presence and absence of cofactor, NADPH-generating system [1 mM
NADP (pH 7.4), 5 mM glucose 6-phosphate (pH 7.4), and 1 unit/ml glucose-6-phosphate
dehydrogenase]. Reactions were initiated by adding the cofactor mix and terminated at
designated time points (0, 15, 30, and 60 min) with the addition of stop reagent (adding equal
volume of ice cold acetonitrile). The samples were centrifuged 10,000 rpm for 10 min at 4oC.
The supernatants were collected and analyzed using ultra performance liquid chromatography
(UPLC)/mass spectrometry/mass spectrometry.
The UPLC system consisted of a Waters Acquity UPLC (Milford, MA) equipped with a
binary solvent manager, vacuum degasser and an auto sampler. Chromatographic separations
were performed on an Atlantis dC18 column (2.1 X 50 mm). The mobile phase consisted of 10
mM ammonium acetate containing 0.1% acetic acid and methanol (25:75, v/v) and pumped at a
flow rate of 0.18 ml/min. The injection volume was 10 μl. A Micromass Quattro MicroTM system
(Waters Corp., Manchester, UK) equipped with electrospray ionization source was used for the
mass spectrophotometric detection. The electrospray ionization source was operated in positive
ionization mode. The acquisitions were performed using multiple reaction monitoring. The mass
transitions chosen for quantitation were m/z 405 → m/z 181 for AZ66 and m/z 448 → m/z 285
for aripiprazole (internal standard). The mass spectrophotometer parameters were optimized for
maximum analyte detection: capillary voltage 4.88 kV, cone voltage 44 V, and argon was used
as the collision gas at 3.5 × 10−3 Pirani. Collision energies were set at 30 and 21 eV for AZ66
and aripiprazole, respectively.
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2.2.3 In Vivo Metabolism Studies. To further evaluate the metabolic stability of AZ66,
pharmacokinetic studies were performed in vivo. Briefly,blood samples from male, Sprague
Dawley rats (n=5) outfitted with indwelling catheters in the jugular vein were collected. An initial
blood volume of 0.1 ml was withdrawn to clear the line. A fresh syringe was used to withdraw a
0.15 ml blood sample. This and all subsequent blood samples were placed in heparinized
microfuge tubes at 0⁰C. The rats were administered 20 mg/kg AZ66 orally (p.o.). Timed blood
samples were then collected for up to 36 h. For each blood sample, plasma was separated by
centrifugation at 10,000 rpm for 10 min at 4⁰C. AZ66 was quantified using ultra performance
liquid chromatography/ mass spectrometry/mass spectrometry as described above.

2.2.4 Synthesis of AZ66.The synthetic scheme for AZ66 is shown in Fig. 2.1.
Commercially available 4-fluoroaniline (1), hydrochloric acid was refluxed in water with NH4SCN
for 4 h to afford compound 2 after recrystallization from ethanol. A solution of bromine in
chloroform was added to compound 2 at 0oC and subsequently refluxed for 2 h to afford
compound 3. Compound 3 was stirred with KOH to afford compound 4. Compound 4 was
treated with carbonyl-1,1'-diimidazole under reflux for 3 h to provide the fluorinated
benzothiazolone 5. Benzothiazolone 5 was alkylated with 1,4-dibromopentane in DMF at 60oC
over 3 h to afford compound 6. Compound 6 was reacted with commercially available
cyclohexyl piperazine to afford AZ66. AZ66 was subsequently converted to the hydrochloride
salt for biological studies. Elemental analysis (C, H, N) of AZ66 was determined using a PerkinElmer CHN/SO Series II Analyzer. Obtained results were within 0.4% of the theoretical values.
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Figure2.1.Synthesis of AZ66.Reagents and conditions: (a) NH4SCN, H2O, reflux, 4 h; (b) Br2, CHCl3, 1 h at 0 C,
reflux, 2 h (c) KOH (d) Gl. acetic acid (e) Carbonyl 1,1' diimidazole, THF, reflux, 3 h; (f) 1,4-dibromopentane , K2CO3,
o
DMF, 60 C, 3 h; (g) cyclohexyl piperazine, K2CO3, TBAI, ACN, reflux, 6 h.

2.3 Results
2.3.1 Competition Binding Assays. The average binding affinities for CM156 and its
analogs at both sigma-1 and sigma-2 receptors are shown in Table 2.1.Specifically, the addition
of a methyl group to prevent N-dealkylation displayed no significant differences on either sigma1 or sigma-2 receptor binding affinity. Furthermore, in an attempt to make the structure more
electronegative, fluoride and oxygen groups were added and also demonstrated no significant
change in sigma receptor binding affinity. However, compounds that were adjusted for bulkiness
and steric hindrance were found to show significantly lower sigma-1 binding affinity.

Table 2.1 Chemical structure and binding affinities of CM156 and its analogs

Structure

Compound name
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Sigma-1 Ki

Sigma-2 Ki

CM156

1.3±0.4

0.6±0.1

AZ57

8.7±1.3

3.1±0.2
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AZ59

8.9±1.6

0.99±0.2

AZ60

92±9.8

5.5±1.1

AZ66

1.2±0.2

0.31±0.1

AZ68

2.1±.44

0.22±0.1

AZ70

>10,000

>1,000

AZ71

>500

>1,000

AZ72

>1,000

>100

AZ73

>10,000

>500
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AZ74

>10,000

>500

AZ77

2.3±0.5

0.8±0.04

AZ78

7.2±1.2

.50±0.3

AZ81

14.3±1.4

13.8±1.3

AZ87

6.2±2.0

6.4±0.9

AZ93

>1,000

~5

AZ97

>1,000

~10
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AZ98

>1,000

~5

AZ99

>1,000

~10

AZ103

>500

~50

AZ104

>1,000

~5

AZ106

>1,000

~50
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AZ108

>1,000

~10

AZ113

>10,000

>500

AZ116

>500

>100

AZ121

>500

~5

AZ122

>500

~10

MES71.2

26.7±1.4

3.0±0.1

MES74.2

318±49

4.7±0.2

MES79.2

283±14

1.1±0.3

MES83.2

45.6±2.9

0.9±0.2

Affinities (Ki in nM) were determined in tissue or cell homogenates. The values in this table represent the mean +
S.E.M. from replicate assays. Values of >10,000 signify that there was less than 30% displacement of the radioligand
at that concentration.

3.3.2 In Vitro Metabolism Studies. The in vitro half-life of CM156 and four other CM156
analogs that demonstrated high sigma receptor binding affinity with desirable structural
modifications were evaluated in rat liver microsomes. AZ66 displayed the longest half life (115.6
min), significantly longer than its parent compound CM156 (4.6 min).
Table 2.2. In vitro half-life (min) in liver microsomes, prepared from rat, of CM156 and redesigned analogs

Compound
CM156
AZ57
AZ66
AZ68
AZ77

Half-life
4.6
68.0
115.6
47.1
14.8
33

3.3.3 In Vivo Metabolism Studies. Based on the in vitro metabolism results, coupled with
the binding affinity and chemical structure, AZ66 was evaluated in vivo. Similar to the in vitro
results, AZ66 was found to have a significantly longer half-life in vivo when compared with
CM156 (Table 3). Additionally, the pharmacokinetic parameters associated with oral dosing of
AZ66 (20 mg/kg) was shown to have a drugable-like profile (Table 4).
Table 2.3. In vivo half-life (min) of CM156 (5 mg/kg, i.v.) and AZ66 (2.5 mg/kg, i.v.) evaluated in blood samples
from male, Sprague Dawley rats

Compound
CM156
AZ66

Half-life
65.2 ± 4.1
129.2

Table 2.4. Pharmacokinetic profile of AZ66 (20 mg/kg, p.o.)evaluated in blood samples from male, Sprague
Dawley rats

Parameter
Area under the curve (AUC)
Half life, T1/2
Maximum concentration, Cmax
Mean residence time
Volume of distribution, Vd
Apparent oral clearance at
steady state, Clss/F
Time to reach maximum
concentration, Tmax
Oral bioavailability

Value
158.22 ± 2.79 µg-h/ml
8.79 ± 0.10 h
0.30 ± 0.02 µg/ml
8.82 ± 0.24 h
78.06 ± 0.85 l/kg
6.15 ± 0.11 l/h/kg
2.00 ± 0.22 h
58.17%

2.4 Discussion
CM156 was previously shown to have significant neuroprotective effects against
methamphetamine. However, due to a poor metabolic profile, further studies using CM156 were
halted. In an effort to maintain CM156’s protective profile while increasing its metabolic stability,
a series of compounds were designed, synthesized, and tested for their binding affinity at
sigma-1 and sigma-2 receptors in addition to their in vitro and in vivo half life. The results
presented herein demonstrate several modifications made to enhance metabolic stability have
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no effect on sigma receptor binding affinity and can provide an increase in half-life compared to
CM156. Furthermore, we have identified a lead compound, AZ66 which displays a drugable-like
pharmacokinetic profile.
Development of a novel therapeutic to treat the effects of methamphetamine has
remained largely unsuccessful to date. As previous studies have demonstrated (Matsumoto et
al., 2008; Kaushal et al., 2011; Seminerio et al., 2011), sigma receptors appear to represent a
logical target for pharmacological intervention. Limitations, including the present metabolic
issue, have inhibited the evaluation of any sigma receptor ligand against methamphetamine in
later drug developmental studies. This study, aimed at developing a lead metabolically stable
compound, also provides valuable insight into structure activity relationship (SAR) for sigma
receptor compounds. While the effects of AZ66 against methamphetamine-induced
complications will be the ultimate endpoint, it is important to recognize the functional groups
modified and their impact pharmacologically.
There were four major modifications made, deemed R1, R2, X, and n. Methyl groups
were added at R1 to prevent N-dealkylation while a fluoride group (R2),previously shown to
enhance sigma selectivity, was included

R1
N

to increase the electronegativity of the

N

structure (the same was true for sulfur
being substituted for oxygen at “X”).
N

X

Increased electronegativity was highly
(CH2)n

R2

desired because previous studies have

S

demonstrated a strong link between the electronegativity of a structure and its biological stability
(Barnette, 1984). The size of functional groups, particularly 5 and 6 member rings have
significant effects on stability as well. Therefore, the size of the benzothiazole ring was adjusted
from a 5 member ring to a 6. Of the four major modifications, adjusting the ring size had the
greatest effect on sigma binding affinity. AZ60 and AZ57 differ only by the size of the
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benzothiazole ring yet AZ57 has a 10 fold higher affinity for sigma-1 receptors compared to
AZ60. Other analogs that incorporated minor changes along with an increased ring size
displayed sigma-1 binding affinities in the micromolar range (AZ93, AZ97, AZ98, AZ99, AZ104).
No significant difference in binding affinity was observed when “X” had sulfur exchanged for
oxygen, a more electronegative element. However, as the MES compounds demonstrated,
substitution of oxygen for sulfur in the benzothiazole ring can actually reduce sigma-1 receptor
binding affinity. Similar to previous studies (Berardi et al., 2004), our results demonstrate that
cyclohexylpiperazine and benzo[d]thiazole are important for sigma receptor binding affinity.
Furthermore, the addition of a methyl and fluoride group can provide stability and may prevent
early metabolic breakdown.
AZ66 displayed the longest half-life both in vitro and in vivo when compared to three
other analogs and the parent compound CM156. In addition, AZ66 maintained subnanomolar
affinities at sigma-1 and sigma-2 receptors. These findings are important as modifying CM156
for metabolic stability had no effect on its binding profile yet displayed a more favorable
pharmacokinetic profile when compared to CM156. The modifications made to AZ66, which
included the addition of a methyl group at R1, coupled with a fluoride at R2 and the exchange of
sulfur for oxygen, appear to provide the greatest likelihood of developing a novel sigma receptor
ligand aimed at mitigating the effects of methamphetamine.

2.5 Contributions
Michael Seminerio performed all of the receptor binding experiments.
CM156 and its analogs were synthesized by Dr. Christophe Mésangeau and Ahmed
Abdelazeem in Dr. Christopher R. McCurdy’s lab at University of Mississippi.
National Institute of Drug Abuse (NIDA) gratuitously performed the in vitro metabolism studies.
Dr. Bonnie Avery at the University of Mississippi performed the in vivo metabolism studies.
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CHAPTER 3
EVALUATION OF AZ66 AGAINST THE
BEHAVIORAL EFFECTS OF METHAMPHETAMINE
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3.1 Introduction
Methamphetamine is currently one of the most abused illicit substances worldwide
(Cadet and Krasnova, 2009; Romanelli and Smith, 2006). It is a highly addictive
psychostimulant whose acute effects include hyperthermia, hypertension, severe cardiac
pathologies, and potential convulsions(Cadet and Krasnova, 2009; Lan et al., 1998). Prolonged
abuse of methamphetamine can result in significant neurological changes that lead to addiction,
drug seeking behavior, and eventual drug dependence(Cadet and Krasnova, 2009; Lan et al.,
1998; Romanelli and Smith, 2006; Volkow et al., 2001b). Currently, there is a lack of
medications designed to treat either the detrimental physiologic effects of methamphetamine or
the addiction liability associated with its use. There have been a substantial amount of clinical
trials conducted with drug candidates aimed at treating the addictive properties of
methamphetamine; however at this time there are still no FDA approved pharmacotherapies for
methamphetamine dependence (Karila et al., 2010). Innovative strategies are essential for the
development of pharmaceutical agents intended to treat the negative effects of
methamphetamine abuse.
Sigma receptors represent a novel target for the development of new therapeutics
intended to treatmethamphetamine-induced effects. There are currently two known subtypes of
sigma receptors, designated sigma-1 and sigma-2. Sigma-1 receptors are 223 amino acid
proteins that are distinct from any other known mammalian protein (Hanner et al., 1996). Sigma1 receptors have been cloned and have a high level of homology among differing species
(Hanner et al., 1996). They can translocate between intracellular compartments where they are
able to modulate signaling pathways and intracellular calcium signaling, interact with specific ion
channels, and affect neurotransmitter synthesis, release, and reuptake (Aydar et al., 2002;
Bergeron et al., 1993; Booth and Baldessarini, 1991; Gronier and Debonnel, 1999; Hayashi et
al., 2000; Hayashi and Su, 2003, 2007). Much less is known about sigma-2 receptors, as these
receptors have yet to be cloned and truly selective sigma-2 receptor ligands are currently
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lacking. Sigma-2 receptors are believed to be involved in cellular survival and modulate calcium
signaling through sphingolipid products (Crawford and Bowen, 2002; Crawford et al., 2002;
Vilner and Bowen, 2000; Vilner et al., 1995a).
Methamphetamine, in addition to interacting with monoamine transporters, interacts with
both subtypes of sigma receptors at physiologically relevant concentrations (Nguyen et al.,
2005). Repeated administrations of methamphetamine have been shown to increase binding of
the sigma receptor ligand [3H](+)-pentazocine in the frontal cortex, substantia nigra and
cerebellum, indicative of an increase in sigma receptors in these regions of the brain(Itzhak,
1993). Notably, sigma-1 receptor protein or mRNA was upregulated in the midbrain and the
hippocampus of rats trained to self-administer methamphetamine(Hayashi et al., 2010). These
studies provide evidence that sigma receptors may, in part, be involved in the neuroadaptive
changes that occur with repeated methamphetamine exposures.
The methamphetamine-induced changes in sigma receptor expression levels appear to
have functional and behavioral consequences. Two different sigma receptor antagonists, MS377 ((R)-(+)-1-(4-chlorophenyl)-3-[4-(2-methoxyethyl)piperazin-1-yl]methyl-2-pyrrolidinone Ltartrate) and BMY 14802 (α-(4-flourophenyl)-4-(5-flouro-2-pyrimidinyl)-1-piperazine), have been
shown to prevent augmented responses to repeated methamphetamine administrations in
rodents, using a paradigm known as behavioral sensitization(Takahashi et al., 2000; Ujike et al.,
1992). However, both of these compounds are unable to attenuate acute methamphetamineinduced behaviors (Takahashi et al., 2000; Ujike et al., 1992). Additionally, the selective sigma
receptor antagonists BD1047([2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(diamino)ethylamine),
BD1063(1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine) and AC927 (1-(2phenethyl)piperidine oxalate), have been shown to attenuate many acute effects of
methamphetamine, including methamphetamine-induced increases in locomotor activity and
hyperthermia in rodent models (Seminerio et al., 2011a). These studies indicate that a selective
sigma receptor ligand may attenuate some of the acute effects of methamphetamine
39

administration in addition to preventing the neurological and behavioral changes associated with
repeated methamphetamine exposures. It is yet to be determined as to whether a preferential
sigma receptor ligand can actually reverse, in addition to prevent, the behavioral changes
associated with methamphetamine-induced behavioral sensitization.
The purpose of the present study was to determine if the preferential sigma receptor
ligand, AZ66 (3-(4-(4-cyclohexylpiperazin-1-yl)pentyl)-6-flourobenzo[d]thiazol-2(3H)-one), is
able to attenuate the acute behavioral effects of methamphetamine and in addition, prevent the
development and block the expression of methamphetamine-induced behavioral sensitization.
AZ66 is an optimized sigma receptor ligand derived from a previously studied selective sigma
receptor antagonist, CM156 (3-(4-(4-cyclohexylpiperazin-1-yl)butyl)benzo[d]thiazole-2(3H)thione) that has been reported to attenuate many cocaine-induced behaviors (Xu et al., 2010).
Further drug development of CM156 was halted due to an exceedingly short half-life (Xu et al.,
2010), and AZ66 was synthesized to avoid the metabolism issues associated with CM156.
Herein, we report that AZ66, a novel sigma receptor preferring ligand, is capable of being
administered orally, and attenuates many methamphetamine-induced behaviors, including the
development and expression of behavioral sensitization.

3.2 Materials and Methods
3.2.1 Drugs and Reagents. Methamphetamine hydrochloride was obtained from SigmaAldrich (St. Louis, MO). Radioligands for binding studies were purchased from Perkin Elmer
(Boston, MA). Other chemicals used for the radioligand binding studies were obtained from
standard commercial sources (Sigma-Aldrich, St. Louis, MO).

3.2.2 Animals. Male, Swiss Webster mice (21-30 g, Harlan, Indianapolis, IN; Frederick,
MD) were used in the present experiments. The mice were housed in groups of 4-6 with a
12:12-h light/dark cycle and ad libitum food and water. Each cage was made from polysulfone
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and provided 542 cm2of floor space (Tecniplast, Philadelphia, PA), which was covered with corn
cob bedding and packing material (ULINE, Waukegan, IL). The mice were acclimated for one
week before being used in experiments and they were randomly assigned to their treatment
groups. Two different shipments of mice were used for each experimental group, regardless of
the sample size. All procedures were performed as approved by the Institutional Animal Care
and Use Committees at the West Virginia University Health Sciences Center and the University
of Mississippi.

3.2.3 Radioligand Binding Studies. The radioligand binding assays were preformed in rat
brain homogenates using methods previously described in detail (Matsumoto et al., 1995;
Matsumoto et al., 2008). Briefly, sigma-1 receptors were labeled with 5 nM [3H](+)-pentazocine
and sigma-2 receptors were labeled with 3 nM [3H]di-o-tolylguanidine (DTG)in the presence of
300 nM (+)-pentazocine to block sigma-1 receptors. Nonspecific binding was determined in the
presence of 10 µM haloperidol. All of the assays were terminated with the addition of ice-cold
buffer and rapid vacuum filtration over glass fiber filters. Separate synthetic batches of AZ66
were used in this study and their Ki values were averaged together to obtain a mean binding
affinity.

3.2.4 Locomotor Activity. Locomotor activity was measured as an index of the stimulant
effects of methamphetamine using an automated activity monitoring system (San Diego
Instruments, San Diego, CA). The mice were given 30-60 min to acclimate to the testing room
before being habituated to the testing chambers for an additional 30 min. Each testing chamber
consisted of a 16 x 16 photobeam array to detect lateral movements and a separate 16
photobeam array to detect rearing by the animals. Ambulatory, fine, and rearing movements
were quantified to give an overall locomotor activity score.

41

Mice (n=24) were divided randomly into four treatment groups for the dose response
study. They received a pretreatment of saline 15 min prior to a dose of methamphetamine (0.15.0 mg/kg, i.p.). The mice were then returned to the testing chambers and their activity was
quantified for 30 min.
For the acute locomotor studies, mice (n=65) were randomly assigned into a treatment
group and pretreated with either saline or AZ66 (0-20 mg/kg, i.p), followed 15 min later by either
saline or a stimulant dose of methamphetamine (1 mg/kg, i.p.). The mice were then returned to
the testing chambers and their activity was quantified for the next 30 min. The evaluation of
AZ66 in combination with saline or methamphetamine allowed the determination of the effects
of AZ66 alone, as well as its ability to mitigate the stimulant actions of methamphetamine.
For the oral administration studies, mice (n=42) were pretreated by oral gavage (p.o.)
with either distilled water (0.1 ml/10 g) or AZ66(20-30 mg/kg) and locomotor activity was
recorded for 30 min after receiving an i.p. injection of either a stimulant dose of
methamphetamine (1 mg/kg) or saline (0.1 ml/10 g). Pretreatment time was 120 min, based on
the pharmacokinetic parameters (Tmax )of AZ66.

3.2.5 Behavioral Sensitization. The mice were acclimated to the treatment room for 60
min and then individually to a testing chamber for 30 min on each day. Locomotor activity was
monitored on Days 1, 2, 3, 4, 5, 6, 7 and 15 for 30 min immediately after the treatments by using
an automated activity monitoring device (San Diego Instruments, San Diego, CA).
For the dose response study, mice (n=12) were randomly assigned to one of four
treatment groups. On Days 1-7, mice received saline pretreatment followed 15 min later by
either saline or methamphetamine (0.1, 0.5, or 1 mg/kg, i.p.). After an 8-day drug-free period,
which allowed the drugs and their metabolites to be washed out, mice were administered either
saline or methamphetamine (0.1, 0.5, 1 mg/kg, i.p.).
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For the development of sensitization studies, mice (n=36) were randomly assigned to
one of six treatment groups as shown in Table 1 and injected i.p. once a day for seven
consecutive days. The two injections making up each treatment were separated by a 15 min
pretreatment period; the dose of methamphetamine used was 1 mg/kg. Treatments on Days 1
to 7 were followed by an 8-day drug-free period, and then all of the mice were challenged on
Day 15 with methamphetamine (1 mg/kg i.p.).
For the expression of sensitization studies, mice(n=42) were randomly assigned to one
of six treatment groups as shown in Table 1and injected once a day (i.p.) for seven consecutive
days with either saline or methamphetamine (1 mg/kg, i.p.). After an 8-day drug-free period,
pretreatment with AZ66 (10-20 mg/kg, i.p.) or saline was administered 15 min prior to
methamphetamine (1 mg/kg, i.p.).

3.2.6 Data Analyses. The data from the radioligand binding assays were analyzed using
GraphPad Prism 4.0 (San Diego, CA) to calculate IC50 values. Apparent Ki values were then
calculated using the Cheng-Prusoff equation and Kd values determined in separate saturation
assays(Cheng and Prusoff, 1973). The data from the acute locomotor activity measurements,
development and expression of sensitization studies were analyzed using GraphPad Prism 4.0
(San Diego, CA) using an analysis of variance (ANOVA). Significant ANOVAs were followed by
post-hocDunnett’s tests for comparisons to control or Bonferroni’s tests for pairwise
comparisons. p<0.05 was considered statistically significant for all behavioral tests.

Table 3.1. Treatment schedule for sensitization experiments
A. Development of sensitization

Group

Day 1-7

Day 8-14

Day 15

1

Sal + Sal

NT

Sal + Meth
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2

Sal + Meth

NT

Sal + Meth

3

AZ66 (10 mg/kg) + Meth

NT

Sal + Meth

4

AZ66 (20 mg/kg) + Meth

NT

Sal + Meth

5

AZ66 (10 mg/kg) + Sal

NT

Sal + Meth

6

AZ66 (20 mg/kg) + Sal

NT

Sal + Meth

B. Expression of sensitization

Group

Day 1-7

Day 8-14

Day 15

1

Sal + Sal

NT

Sal + Meth

2

Sal + Sal

NT

AZ(10 mg/kg) + Meth

3

Sal + Sal

NT

AZ (20 mg/kg) + Meth

4

Sal + Meth

NT

Sal + Meth

5

Sal + Meth

NT

AZ (10 mg/kg) + Meth

6

Sal + Meth

NT

AZ (20 mg/kg) + Meth

n = 6-10/group. NT = no treatment. Meth = methamphetamine (1 mg/kg); Sal = saline; AZ = AZ66.
All compounds were administered intraperitoneally.

3.3 Results
3.3.1 Competition Binding Assays. The average binding affinities of AZ66 for sigma-1
and sigma-2 receptors, in addition to seven other sites are listed in Table 3.2. AZ66 bound to
both sigma-1 and sigma-2 receptors with nanomolar affinities (batch 1 had a sigma-1 affinity of
1.20 ± 0.15 nM and a sigma-2 affinity of 0.31 ± 0.09 nM; batch 2 had a sigma-1 affinity of 3.50 ±
0.13 nM and a sigma-2 affinity of 0.66 ± 0.15 nM). In addition, AZ66 had a >200 fold preference
for sigma receptors compared to the other sites tested. However, AZ66 displayed a moderate to
low affinity for the serotonin transporter, serotonin (5-HT2) receptor, dopamine (D2) receptor,
and dopamine transporter.
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Table 3.2 Binding affinities of AZ66 for sigma receptors, monoamine transporters, and non-sigma sites
Radioligand

Nonspecific binding

Tissue Ki

Sigma receptors:

σ1

5 nM [3H](+)-pentazocine

10 µM haloperidol

Rat brain

2.4 ± 0.63

σ2

3 nM [3H]di-o-tolylguanidine

10 µM haloperidol

Rat brain

0.51 + 0.15

Monoamine transporters:

Dopamine

0.5 nM [3H]WIN 35,428

50 µM cocaine

Rat striatum

872 + 122

Serotonin

0.2 nM [3H]paroxetine

1.5 µM imipramine

Rat brainstem

612 ± 44

Norepinephrine

0.5 nM [3H]nisoxetine

4 µM desipramine

Rat cerebral cortex

Opioid

1 nM [3H]naloxone

1 µM naloxone

Rat brain

>10,000

5-HT2

2 nM [3H]ketanserin

1 µM mianserin

Rat brain

535 ± 51

Dopamine (D2)

5 nM [3H](-)-sulpiride

1 µM haloperidol

Rat brain

1183 ± 272

NMDA/PCP

5 nM [3H]TCP

10 µM cyclazocine

Rat brain

>10,000

>10,000

Non-sigma sites:

Affinities (Ki in nM) were determined in rat brain. The values in this table represent the mean + S.E.M. from replicate
assays.NMDA =N-Methyl-D-aspartic acid; PCP = Phencyclidine; TCP = Tenocyclidine.

3.3.2.Locomotor Activity. Methamphetamine produced an inverted U-shaped dose
response for locomotor activity (Fig. 3.1A); peak locomotor stimulant effects were observed at 1
mg/kg, which was thereafter administered as the challenge dose of methamphetamine for all
further studies. One way ANOVA confirmed that the differences between methamphetamine
doses were statistically significant (F(4,29)=10.92, p<0.0001). Post-hoc analysis using Dunnett’s
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multiple comparison tests revealed that three doses of methamphetamine (0.5, 1.0, 5.0 mg/kg,
i.p.) were significantly different from the saline control (Fig. 3.1A).
Pretreatment with AZ66 prior to a stimulant dose of methamphetamine significantly
attenuated methamphetamine-induced hyperactivity (Fig. 3.1B). One way ANOVA confirmed a
significant difference between treatment groups (F(4,46)=12.81, p<0.0001). Post-hoc analysis
using Bonferroni’s multiple comparison tests revealed a significant attenuation of
methamphetamine-induced hyperactivity at two doses of AZ66 (10 and 20 mg/kg, i.p.). In the
absence of methamphetamine, AZ66 had no significant effect on locomotor activity (Fig. 3.1B).
To further evaluate the drug-like characteristics of AZ66, oral administration studies were
conducted (Fig. 3.1C). One way ANOVA confirmed that there was a significant difference
between all treatment groups (F(5,41)=19.01, p<0.0001). Post-hoc analysis using Bonferroni’s
multiple comparison tests revealed a significant attenuation of methamphetamine-induced
hyperactivity at both doses of AZ66 (20 and 30 mg/kg, p.o.). Similar to the i.p. studies, AZ66
displayed no significant effects in the absence of methamphetamine compared to saline-treated
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mice (Fig. 3.1C).
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Figure3.1. The effects of methamphetamine and AZ66 on locomotor activity. (A) Dose dependent effects of
methamphetamine on basal locomotor activity. Male, Swiss Webster mice (n=6 per group) were injected with saline
or methamphetamine (Meth, 0.1, 0.5, 1.0, 5 mg/kg, i.p.) and their activity was quantified for 30 min.
Methamphetamine caused an inverted dose response on locomotor activity. Data are reported as mean ± SEM.
*p<0.05, **p<0.01 vs. saline, post-hoc Dunnett’s test. (B) Effects of AZ66 on locomotor activity following
methamphetamine treatment. Male, Swiss Webster mice (n=6-10 per group) were pretreated with saline or AZ66 (1,
10, 20 mg/kg, i.p.) 15 min prior to saline (white bars) or methamphetamine (1 mg/kg, i.p., black bars) administration.
AZ66 significantly attenuated the locomotor stimulant effects of methamphetamine. Data are reported as mean ±
SEM. ***p<0.001 vs. saline; #p<0.05, ##p<0.01 vs. Meth, post-hoc Tukey’s test. (C) Effects of orally administered
AZ66 on methamphetamine-induced increases in locomotor activity. Mice (n=6-10 per group) pretreated with oral
administration of distilled water (0 mg/kg AZ66) were challenged (i.p.) with either a stimulant dose of
methamphetamine (1 mg/kg, i.p., +Meth, black bars) or saline (-Meth, white bars); all other animals pretreated with
oral dosing with AZ66 (20-30 mg/kg) were challenged with methamphetamine (1 mg/kg, i.p., black bars) or saline (Meth, white bars). Animals received distilled water or AZ66 120 min prior to methamphetamine administration.
Methamphetamine-induced increases in locomotor activity were significantly attenuated by pretreatment with 20 and
30 mg/kg, p.o. AZ66. Data are reported as mean ± SEM. ***p<0.001 vs. saline; #p<0.05, ###p<0.001 vs. Meth, posthoc Tukey’s test.

3.3.3. Behavioral Sensitization. When a dose response experiment was conducted to
determine the optimal dose of methamphetamine needed to produce behavioral sensitization
(Fig. 3.2), methamphetamine dose-dependently increased locomotor activity on Days 1-7, and
remained significantly higher on the challenge day (Day 15) when compared to Day 1. ANOVA
confirmed a significant difference between the experimental groups on all of the treatment days
(F(3,31)=162, p<0.0001). Repeated administration of methamphetamine on Days 1-7 resulted in
behavioral sensitization, which was measured as an enhanced response to methamphetamine
on Day 15 (0.5 mg/kg, q=2.94, p<0.05; 1.0 mg/kg, q=3.15, p<0.05; post hoc Dunnett’s
test).Based on the larger increases in total locomotor activity, 1 mg/kg of methamphetamine
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was used as the challenge dose in subsequent behavioral sensitization studies.
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Figure 3.2. Dose dependent effects of methamphetamine on behavioral sensitization. Male, Swiss Webster
mice (n=12) were injected with saline or methamphetamine (Meth, 0.1, 0.5, 1 mg/kg, i.p.) on Day 1-7. Following an 8day drug-free period, the animals were challenged with either saline or methamphetamine (0.1, 0.5, 1 mg/kg, i.p.) on
Day 15. Repeated administration of methamphetamine (0.5 and 1 mg/kg) on days 1-7 resulted in behavioral
sensitization on day 15. Data are reported as mean ± SEM. *p<0.05, **p<0.01 vs. Meth (Day 1), post-hoc Dunnett’s
tests.

3.3.4 Development of Behavioral Sensitization. ANOVA demonstrated a significant
difference between the treatment groups on all treatment days: Day 1 (F(5,35)=16.89,
p<0.0001); Day 2 (F(5,35)=43.95, p<0.0001); Day 3 (F(5,35)=25.98, p<0.0001); Day 4
(F(5,35)=27.30, p<0.0001); Day 5 (F(5,35)=27.55, p<0.0001); Day 6 (F(5,35)=25.21, p<0.0001);
Day 7 (F(5,35)=29.56, p<0.0001); and Day 15 (F(5,35)=13.00, p<0.0001). Post-hoc Dunnett’s
test confirmed that methamphetamine-treated mice displayed a significantly higher locomotor
activity in comparison to the saline-treated controls for Days 1-7. Additionally, with the exception
of the methamphetamine-treated group that demonstrated an elevated locomotor response on
Days 1-7, none of the other groups had significantly different locomotor activity as compared to
the saline control group for any of the treatment days. Pretreatment with AZ66 (10 and 20
mg/kg, i.p.) before methamphetamine administration on Days 1-7 significantly attenuated
methamphetamine-induced increases in locomotor activity compared to saline +
methamphetamine treated mice. On the challenge day (Day 15), when each of the groups were
administered methamphetamine, mice that received methamphetamine on Days 1-7 exhibited a
significantly higher locomotor activity than mice that received saline on Days 1-7 (t=7.22,
p<0.001), indicative of behavioral sensitization (Fig. 3.3). Mice that received AZ66 as a
pretreatment to methamphetamine on Days 1-7 demonstrated a significantly lower locomotor
count compared to mice who received saline prior to methamphetamine on Days 1-7: AZ66 10
mg/kg (t=4.39, p<0.01), AZ66 20 mg/kg (t=5.03, p<0.001) (Fig. 3.3).
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Figure3.3. Effects of AZ66 on the development of behavioral sensitization to methamphetamine. Male, Swiss
Webster mice were injected (i.p.) with either saline or AZ66 (10 or 20 mg/kg) followed 15 min later with either saline
or methamphetamine (Meth, 1 mg/kg) once a day for seven days. Following an 8-day drug-free period (Day 15), all
of the mice were injected (i.p.) with saline, followed 15 min later with methamphetamine (1 mg/kg). Pretreatment with
AZ66 (10 or 20 mg/kg) on Days 1-7 significantly blocked the development of sensitization. Data are reported as
mean ± SEM. ***p<0.001 vs. saline; #p<0.05, ##p<0.01, ###p<0.001 vs. Meth, post-hoc Tukey’s tests.

3.3.5. Expression of Behavioral Sensitization. ANOVA confirmed a significant difference
between the methamphetamine-treated mice and saline-treated mice on Days 1-7: Day 1
(F(5,41)=23.67, p<0.0001); Day 2 (F(5,41)=43.07, p<0.0001); Day 3 (F(5,41)=60.16, p<0.0001);
Day 4 (F(5,41)=54.48, p<0.0001); Day 5 (F(5,41)=43.45, p<0.0001); Day 6 (F(5,41)=36.70,
p<0.0001); Day 7 (F(5,41)=40.05, p<0.0001). On the challenge day (Day 15), there was still a
significant difference between the treatment groups (F(5,41)=25.34, p<0.0001), and
pretreatment with AZ66 significantly attenuated hyperactivity in mice that were sensitized
(methamphetamine treatments on Days 1-7). Post-hoc Bonferroni’s tests confirmed that
pretreatment with both doses of AZ66 prior to methamphetamine administration on Day 15
caused a significant attenuation of methamphetamine-induced hyperactivity in mice receiving
saline on Days 1-7 (10 mg/kg, t=4.03, p<0.01; 20 mg/kg, t=4.67, p<0.001) and mice receiving
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methamphetamine on Days 1-7 (10 mg/kg, t=5.03, p<0.001; 20 mg/kg, t=6.75, p<0.001). AZ66
pretreatment also attenuated acute increases in mice only receiving methamphetamine on Day
15 (saline treatments on Days 1-7) (10 mg/kg, t=6.15, p<0.001; 20 mg/kg, t=7.12, p<0.001).
Both doses of AZ66 were shown to have no significant effects in the absence of
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methamphetamine compared to saline treated mice (Fig. 3.4).
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Figure3.4.Effects of AZ66 on the expression of behavioral sensitization to methamphetamine. Male, Swiss
Webster mice were injected (i.p.) with saline or methamphetamine (Meth, 1 mg/kg) once a day for seven days (Days
1-7). Following an 8-day drug-free period (Day 15), mice were injected (i.p.) with saline or AZ66 (10 or 20 mg/kg),
followed 15 min later with methamphetamine (1 mg/kg, Meth). Pretreatment with AZ66 (10 or 20 mg/kg) on Day 15
significantly blocked the expression of sensitization. Data are represented as mean ± S.E.M., ***p<0.001 and
##p<0.01, ###p<0.001, post-hoc Tukey’s tests (comparing saline + methamphetamine treatment with AZ66 +
methamphetamine treatment in groups treated during days 1-7 with either saline or methamphetamine, respectively).

3.4 Discussion
Previously studied sigma receptor ligands attenuate many of the behavioral effects of
methamphetamine administration in rodent models (Matsumoto et al., 2008; Nguyen et al.,
2005; Rodvelt et al., 2011; Takahashi et al., 2000; Ujike et al., 1992). Earlier studies have
focused on the acute locomotor stimulant effects of methamphetamine in addition to the
prevention of methamphetamine-induced behavioral sensitization. This study is the first to our
knowledge showing that an optimized, orally bioavailable sigma receptor ligand attenuates the
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expression of methamphetamine-induced behavioral sensitization, in addition to mitigating the
acute locomotor stimulant effects of methamphetamine and preventing the development of
methamphetamine-induced behavioral sensitization.
Radioligand binding studies demonstrated that AZ66 displays high nanomolar affinities
for both sigma-1 and sigma-2 receptors and a >200 fold preference for sigma receptors
compared to any other site tested. These values are significant in that AZ66 represents an orally
active, metabolically optimized ligand for further drug development that retains sigma receptor
affinity and selectivity.
In this study, both i.p. injection and p.o. dosing of AZ66 attenuated methamphetamineinduced increases in acute locomotor activity. Additionally, both doses of AZ66 attenuated
methamphetamine-induced locomotor activity while producing no effects on their own, a
characteristic that is indicative of antagonist-like properties. This is consistent with past reports
of sigma receptor antagonists attenuating these behaviors (Matsumoto et al., 2008; Nguyen et
al., 2005; Seminerio et al., 2011a). Data from the present study supports a role for sigma
receptors in these effects and also shows that a sigma receptor preferring compound
administered orally can mitigate methamphetamine-induced hyperactivity. These protective
effects are likely to involve both subtypes of sigma receptors; however being that AZ66 has
mixed affinity for both subtypes, the determination as to which subtype is responsible for the
actions presented here cannot conclusively be made. Nevertheless, antisense oligonucleotide
studies have shown that sigma-1 receptors play a role in the acute locomotor stimulant effects
of methamphetamine (Nguyen et al., 2005). Knockdown of sigma-1 receptors mitigate the
locomotor stimulant effects of methamphetamine and similar results are obtained through the
use of sigma receptor antagonists (Nguyen et al., 2005). However, sigma-1 receptor knockout
mice still respond to methamphetamine suggesting a compensatory role for sigma-2 receptors
(Fontanilla et al., 2009), which is consistent with the reported ability of sigma-2 receptor
agonists to produce motor activating effects (Walker et al., 1993). It is thus likely that AZ66 acts
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as a sigma receptor antagonist at both subtypes to block the acute hyperactivity induced by
methamphetamine.
AZ66 also prevents the development of methamphetamine-induced behavioral
sensitization. These results demonstrate the ability of AZ66 to block the neurological changes
associated with repeated administration of psychostimulants such as methamphetamine.
Repeated treatment with methamphetamine causes long lasting neuroadaptations within
regions of the brain associated with reward (White and Kalivas, 1998). Behavioral sensitization
is a quantifiable measure of these neuroadaptations and in this study, AZ66 attenuated the
development of methamphetamine-induced behavioral sensitization. These results suggest that
sigma receptors play a role in the establishment of sensitization and AZ66 may provide
protective effects by blocking the evolution of neuroadaptations necessary for the development
of behavioral sensitization. Neurons located in the ventral tegmental area (VTA) are believed to
be responsible for the development of sensitization, and sigma receptors are widely distributed
in the VTA (Graybiel et al., 1989). A number of other sigma receptor ligands have previously
been shown to attenuate the development of sensitization to psychostimulants (Takahashi et al.,
2000; Ujike et al., 1996; Ujike et al., 1992; Witkin et al., 1993; Xu et al., 2010); however the
mechanism by which these events occur remain largely unknown.
Sigma receptors are involved in several aspects of neuroplasticity, including neurite
outgrowth, and sigma receptor ligands modulate these processes (Hayashi and Su, 2005;
Takebayashi et al., 2002, 2004). The neurologic changes associated with augmented locomotor
responses to repeated administrations of methamphetamine may occur through neuroplasticity
mediated in part by sigma receptors. Sigma receptors modulate dopaminergic
neurotransmission in a variety of ways through protein kinase C, calcium/calmodulin, and
calcium signaling (Derbez et al., 2002; Kalivas and Stewart, 1991). Another potential
mechanism by which sigma receptors may modulate neuroplasticity is through the
phosphorylation of CREB (Yang et al., 2009). CREB phosphorylation has been shown to be
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altered in discrete regions of the brain following methamphetamine-induced behavioral
sensitization (McDaid et al., 2006); however, the exact way in which this relates to behavioral
consequences has yet to be determined. Other studies demonstrate close interactions between
sigma receptors and the dopamingeric system in regions of the brain responsible for motor
function, as well as sites likely responsible for the development of methamphetamine-induced
behavioral sensitization (Graybiel et al., 1989; Gundlach et al., 1986; Largent et al., 1984;
Takahashi et al., 2001; Tam, 1983; Ujike et al., 1992).
In addition to blocking the development of behavioral sensitization, AZ66 significantly
reversed the expression of methamphetamine-induced sensitization. Expression of sensitization
is a clinically relevant behavioral paradigm that measures neuroadaptations that have already
occurred after repeated methamphetamine exposures(Chen et al., 2009). AZ66 blocked the
expression of sensitization when administered on the challenge day (Day 15), further implicating
a role for sigma receptors in sensitization. While neurons located in the VTA are important for
the development of sensitization, the nucleus accumbens (NAc) is an essential region
responsible for the expression of sensitization (Di Chiara et al., 2004). Sigma receptor ligands
have been shown to modulate dopamine uptake in the NAc (Thompson et al., 2001) and sigma
receptors may play a role in the reinforcing effects of drugs of abuse by modulating dopamine
levels in the NAc (Ault and Werling, 1999). The ability of AZ66 to reverse the effects are most
likely due to sigma receptor modulation of both dopamine transporters and dopamine levels in
motor and limbic areas of the brain, specifically the NAc. Taken together, sigma receptors
appear to have a modulatory role in both the development and expression of
methamphetamine-induced sensitization.
The majority of clinical research centered on drug addiction and dependence focuses on
the removal of physical dependence and withdrawal syndromes, neglecting the core symptoms
of addiction and molecular etiology of the disease. Sigma receptors represent a novel strategy
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to understanding the molecular basis of drug addiction and may represent a plausible site for
pharmacological intervention.
Data from radioligand binding studies and metabolism studies demonstrate AZ66 is a
sigma receptor preferring ligand with a favorable pharmacological profile. Moreover, AZ66
provides protection against acute and adaptive behavioral effects of methamphetamine while
having no effects on its own. Although additional studies need to be conducted in order to
further characterize AZ66 as a potential medication, the data presented herein support a role for
sigma receptors in the acute and subchronic behavioral effects of methamphetamine.

3.5 Contributions
Michael Seminerio performed the receptor binding experiments, the acute locomotor studies,
the development of sensitization studies and the expression of sensitization studies.
AZ66 was synthesized by Ahmed Abdelazeem in Dr. Christopher McCurdy’s lab.
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CHAPTER 4
EVALUATION OF AZ66 AGAINST
METHAMPHETAMINE-INDUCED
NEUROTOXICITY AND HYPERTHERMIA
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4.1. Introduction
Methamphetamine is an addictive psychostimulant and currently listed as the second
most abused illicit substance in the world (United Nations, 2007). Methamphetamine abuse can
result in several negative consequences including significant neurotoxicity at high or repeated
doses (Cadet and Krasnova, 2009; Kita et al., 2003). Chronic use results in long lasting nerve
terminal degeneration in specific regions of the brain (Cadet and Krasnova, 2009).
Methamphetamine is believed to exert these effects through its interaction with monoamine
transporters, primarily the dopamine transporter (Krasnova and Cadet, 2009; Schep et al.,
2010). This results in the release of dopamine from synaptic vesicles within the nerve terminal
and a resulting release of excess dopamine into the synapse by inhibition of reuptake and
reversal of flow through dopamine transporters (Krasnova and Cadet, 2009; Schep et al., 2010).
This is believed to lead to nerve terminal degeneration through the formation of reactive oxygen
species and reactive nitrogen species (Kita et al., 2003). In addition, high doses of
methamphetamine can lead to life threatening hyperthermia. Methamphetamine-induced
hyperthermia, although often overlooked, has been shown to correlate directly with
methamphetamine-induced lethality and neurotoxicity, suggesting the importance of
understanding this effect (Bowyer et al., 1994).
In addition to affecting dopamine systems and body temperature (Fleckenstein et al.,
2000), methamphetamine interacts with sigma receptors (Itzhak, 1993; Nguyen et al., 2005).
Sigma receptors are unique proteins which are distinct from other known receptors and consist
of at least two subtypes, sigma-1 and sigma-2 (Guitart et al., 2004; Matsumoto et al., 2003; Su
and Hayashi, 2003). They are distributed in the brain and peripheral organs (Itzhak, 1994;
Walker et al., 1990). Of the two subtypes, sigma-1 receptors are localized intercellularly
(Hayashi et al. 2000, 2001) and have been cloned in several species (Mei and Pasternak, 2001;
Prasad et al., 1998). Sigma-1 receptors have important roles in the modulation of several
neurotransmitters by affecting intercellular second messenger systems, particularly calcium
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mobilization(Hayashi et al., 2000; Hayashi and Su, 2001; Hong et al., 2004; Su and Hayashi,
2001). In addition, because of the chaperone like characteristics of sigma-1 receptors, they are
believed to partake in protein-protein interactions and undergo translocation between various
cellular compartments (Hayashi and Su, 2007). Sigma-2 receptors, on the other hand, have not
been cloned and at 18-22 kDa, are smaller than sigma-1 receptors (Hellewell et al., 1994). They
are believed to regulate calcium release from stores within the endoplasmic reticulum (Vilner
and Bowen, 2000) and are implicated in the regulation of cell proliferation and cell viability
(Vilner and Bowen, 1993; Vilner et al., 1995). As with the sigma-1 receptor, sigma-2 receptors
are widely distributed throughout the cell including the mitochondria, endoplasmic reticulum,
lysosome, and plasma membrane (Zeng et al., 2007).
Recent evidence has shown that methamphetamine produces some of its physiological
and behavioral effects through sigma receptors (Nguyen et al., 2005). Specifically, sigma
receptors may play a role in the neurotoxic and hyperthermic effects of methamphetamine
(Kaushal et al., 2012; Kaushal and Matsumoto, 2011; Kaushal et al., 2011; Matsumoto et al.,
2008; Seminerio et al., 2011a). Sigma receptors are found on monoaminergic neurons
(Bastianetto et al., 1995; Booth and Baldessarini, 1991; Gundlach et al., 1986) and modulate
the release of neurotransmitters such as dopamine and serotontin, which has been linked to
neurotoxic consequences and changes in body temperature (Salmi and Ahlenius, 1998;
Schwartz et al., 1995). Previous studies have demonstrated pretreatment with sigma receptor
ligands can attenuate methamphetamine-induced neurotoxicity (Kaushal et al., 2012; Kaushal
and Matsumoto, 2011; Kaushal et al., 2011; Matsumoto et al., 2008; Seminerio et al., 2011a). In
addition, sigma receptor ligands have been shown to modulate thermoregulation (Rawls et al.,
2002).
The present study investigated whether methamphetamine-induced dopaminergic and
serotonergic neurotoxicity and hyperthermia could be prevented using the optimized sigma
receptor ligand AZ66 (3-(4-(4-cyclohexylpiperazin-1-yl)pentyl)-6-flourobenzo[d]thiazol-2(3H)57

one). AZ66 has previously been shown to mitigate many of the behavioral effects of
methamphetamine, including the development and expression of behavioral sensitization
(Seminerio et al., 2012), suggesting its potential importance toward future drug development
studies.

4.2. Materials and Methods
4.2.1 Animals. Male, Swiss Webster mice (21-30 g, Harlan, Indianapolis, IN; Frederick,
MD) were used for all experiments. Animals were housed 1-5 per cage with a 12:12h light/dark
cycle and ad libitum food and water. They were allowed one week to acclimate following their
arrival before being used in an experiment. All procedures were approved by the Institutional
Animal Care and Use Committee at West Virginia University.

4.2.2 Drugs and Treatment. (+)-Methamphetamine hydrochloride was purchased from
Sigma-Aldrich (St. Louis, MO) and sterile saline solution was purchased from Teknova
(Hollister, CA). The sigma receptor ligand, AZ66, was synthesized as previously described
(Seminerio et al., 2012). All drug solutions were made with saline, and the solution volumes
were administered relative to body weight (0.1 ml/10 g).
Mice were randomly divided into groups that were injected with saline (0.1 ml/10 g, i.p.) or
AZ66 (10 mg/kg, i.p.) 15 min prior to injection with saline or methamphetamine (5 mg/kg, i.p.).
The dose of AZ66 was chosen based on previous studies which demonstrated significant
effects against methamphetamine while exerting no effects on its own (Seminerio et al., 2012).
Similarly, previous work in our lab has shown neurotoxic dosing with methamphetamine
produces a dose-dependent depletion of dopamine levels in the mouse striatum, with 5 mg/kg
being the lowest dose producing statistically significant effects (Kaushal et al., 2011). Therefore,
10 mg/kg of AZ66 and 5 mg/kg of methamphetamine was used.
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Each group of mice received their treatment a total of four times at 2 h intervals. One hour
after each treatment, the body temperatures of the mice were recorded. To allow sufficient time
for the methamphetamine-induced degeneration of nerve terminals to occur, the animals were
sacrificed and the brains removed one week later (Cappon et al., 2000). The striata of the mice
were then collected on ice and evaluated for dopamine levels and dopamine transporter (DAT)
expression. The detailed procedure for each of the end points is provided below.

4.3.3 Dopamine Assays. The mice (n=5/group) were randomly assigned to one of the
following treatments: (1) Saline + Saline; (2) Saline + METH (1.25, 2.5, or 5 mg/kg); (3) CM156
(5, 10, or 20 mg/kg) + Saline; (4) CM156 (5, 10, or 20 mg/kg) + METH (1.25, 2.5, or 5 mg/kg).
The first compound in each treatment group (Saline or CM156) was administered 15 min prior to
the second injection (Saline or METH). All of the combinations of treatments were given i.p. at 2
hour intervals totaling four times.
To allow sufficient time for the METH-induced degeneration of dopamine nerve terminals
to occur, the animals were sacrificed and the brains removed one week following treatment
(Cappon et al., 2000). The striatum and cerebellum were dissected from each treated mice and
then frozen in liquid nitrogen. The tissues were stored at -80o C for later analysis of dopamine
content.
Using a dopamine research enzyme immunoassay kit and protocols provided by the
manufacturer (Rocky Mountain Diagnostics, Colorado Springs, CO), mouse brain striatal
dopamine were quantified. Brain tissues were homogenized in 0.01 N HCl. Dopamine was
extracted and then acylated to N-acyldopamine using the buffer and reagents provided by the
ELISA kit. Acylated dopamine from the tissue samples was then incubated with solid phase
bound dopamine, dopamine antiserum, and antiserum buffer to compete for a fixed number of
antiserum binding sites. Free antigen and free antigen-antiserum complexes were removed via
wash buffer. The antibody bound to the solid phase dopamine was detected using an anti-rabbit
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IgG-peroxidase conjugate with TMB as the substrate. The amount of antibody bound to the solid
phase dopamine was measured by monitoring the reaction at 450 nm. The solid phase
dopamine measured was inversely proportional to the dopamine concentration of the tissue
sample and was quantified relative to a standard curve of known concentrations.

4.3.4 Serotonin Assays. For assessing the effects of AZ66 and METH on brain serotonin
levels, mice (n=5/group) were randomly assigned to one of four groups described in the
previous dopamine assay section. Similar to the procedure used for the dopamine
measurements, the animals were sacrificed and the brains removed one week following
treatment (Cappon et al., 2000). The striatum and cerebellum were dissected from each treated
mice and then frozen in liquid nitrogen. The tissues were stored at -80o C for later analysis of
serotonin content.
Using a serotonin research enzyme immunoassay kit and protocols provided by the
manufacturer (Rocky Mountain Diagnostics, Colorado Springs, CO), mouse brain striatal
serotonin was quantified. Brain tissues were homogenized in 0.2 M perchloric acid, followed by
centrifugation at 3,000 rpm for 10 min at 4o C. Supernatant was obtained and used for the
serotonin measurements. Serotonin was first quantitatively derivatised into N-acyl5-HT using
the acylation buffer provided with the kit. Acylated serotonin from the tissue samples were then
incubated with solid phase bound serotonin and serotonin antiserum to compete for fixed
number of antiserum binding sites. Free antigen and free antigen-antiserum complexes were
removed by wash buffer. The antibody bound to the solid phase serotonin was detected using
an anti-rabbit IgG-peroxidase conjugate with TMB as the substrate. The amount of antibody
bound to the solid phase serotonin was measured by monitoring the reaction at 450 nm. The
solid phase serotonin measured was inversely proportional to the serotonin concentration of the
tissue sample and was quantified relative to a standard curve of known concentrations.

60

4.3.4 Immunohistochemistry Studies. Striatal sections were assessed for DAT
expression. The mice were randomly assigned to one of the following treatment groups: (1)
Saline + Saline; (2) Saline + METH (5 mg/kg); (3) AZ66 (10 mg/kg) + METH (5 mg/kg); (4) AZ66
(10 mg/kg) + Saline. The treatments were administered as previously described for the
dopamine assays.
One week following treatment, the mice were perfused transcardially with 0.1 M
phosphate buffered saline (pH 7.4), followed by 4% paraformaldehyde. The brains were further
fixed overnight in 4% paraformaldehyde. Coronal sections (50 µm) of the fixed tissue were
made throughout the rostral-caudal extent of the striatum using a cryostat, and processed in a
free-floating state in 0.1 M Tris-HCl buffered saline (TBS, pH 7.5). The sections were treated
with 0.3 % in H2O2 in TBS for 30 min at room temperature. The sections were then treated with
TBS containing 0.2% Triton X-100 and 1.5% normal goat serum for 30 min at room
temperature. Incubation of the sections with anti-rat DAT antibody (Chemicon International,
Temecula, CA; MAB369, dilution 1:10,000) was performed for 36 h at 4º C. The labeled
sections were then washed twice in TBS and processed using Vectastain Elite ABC (Vector
Laboratories, Burlingame, CA). Sections were then incubated with biotinylated secondary antirat antisera (diluted 1:200) in TBS-NBS for 60 min. This was then followed by incubation of the
sections with avidin-biotinylated peroxidase substrate in TBS for 60 min. The staining was then
visualized by reacting 3, 3’-diaminobendine containing 0.01% H2O2 for 5 min.
The stained sections were mounted onto gelatin-coated slides and dried. The sections
were then dehydrated, cleared, and cover-slipped. The images were captured digitally using a
Leica DMIL microscope (Leica Microsystems, Bannockburn, IL) and optical density readings
were quantified in anterior regions of the striatum using Kodak ID image analysis software. To
obtain the data point for a given animal, the optical density readings from at least three sections
were averaged.
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4.3.5 Body Temperature.
emperature. The mice (n=5) were randomly assigned to treatment groups,
which were the same as those described for the dopamine and serotonin assays. All of the
combinations of drug treatments were given i.p. at 2 h intervals totaling four times. Core body
temperature was measured 1 h following each of the four treatment injections with a Thermalert
TH-S monitor (Physitemp Instruments
nstruments Inc., Clifton, NJ)
NJ). During the temperature measurements,
mice were gently held at the base of the tail and a probe (RET
(RET-3)
3) was inserted approximately
2.5 cm past the rectum into the colon for 8
8-10
10 s until a rectal temperature was maintained for 33
4 s.

Figure 4.1.Repeated dosing paradigm of methamphetamine. Male, Swiss Webster mice were pretreated (i.p.)
with saline or AZ66 (10 mg/kg) followed 15 min later with saline or METH (5 mg/kg). This schedule of treatment was
repeated at 2 hour intervals, a total of four ttimes.
imes. One hour after each of the four injections, the core body
temperature (BT) of the mice were recorded. One week later, the brains were processed according to the designated
study.

4.3.6 Data Analysis. The data from the dopamine and serotonin assays,
immunohistochemical studies and core body temperature readings were evaluated using oneway analysis of variance (ANOVA).
(ANOVA).Post-hoc analyses were performed with Dunnett’s tests
test or
Bonferroni’s tests for comparisons to controls and Tukey’s tests for p
pairwise
airwise comparisons.
comparisons For
all analyses, p<0.05 was considered statistically significant. GraphPad Prism (San Diego, CA)
was used for all data analyses.
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4.3 Results
4.3.1 Neurotoxicity Evaluations
Dopamine assays. Consistent with other investigations, one-way analysis of variance
showed that METH produced a dose dependent reduction of dopamine levels in the striatum
brain region (Fig.4.2; F(3,27)=7.26, p<0.001). Post-hoc Dunnett’s tests revealed that the striatal
changes produced by the following doses of METH differed significantly from the saline control
group: 2.5 mg/kg (q=2.55, p<0.05), 5 mg/kg (q=4.61, p<0.001).
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Figure 4.2. Dose response effects of METH on dopamine (DA) levels in the striatum. Male, Swiss Webster mice
(n = 7-9 per group) were injected (i.p.) with METH (1.25- 5.0 mg/kg, i.p.) or saline (0 mg/kg, i.p.) at 2 hour intervals for
a total of four times. DA levels in the striatum and cerebellum tissues were measured one week later, and data was
reported as mean ± SEM. *p < 0.05, ***p< 0.01 vs. saline.

Figure 4.3 shows the effects of the sigma receptor ligand AZ66 on methamphetamineinduced dopamine depletions in the mouse striatum. Analysis of variance confirmed significant
differences between groups (F(3,36)=13.67, p<0.001). Post-hoc Tukey’s test confirmed that
methamphetamine produced significant decreases in striatal dopamine levels compared to
saline treated animals (q=6.17, p<0.001) and pretreatment with AZ66 significantly attenuated
methamphetamine-induced dopamine depletions (q=8.88, p<0.001). When AZ66 was
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administered alone, the striatal dopamine levels were not significantly changed compared to
saline-treated animals (p>0.05).
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Figure 4.3. Effects of methamphetamine (METH) and AZ66 on dopamine levels in the mouse striatum. Male,
Swiss Webster mice (n = 6-8 per group) were pretreated with saline (SAL) or AZ66 (AZ, 10 mg/kg, i.p.). After 15 min,
the mice were then treated with saline (SAL) or METH (5 mg/kg, i.p.). This treatment schedule was repeated 4 times
at 2 h intervals. One week later, the brain was removed and dopamine levels were measured via ELISA. Data was
reported as mean ± SEM ***p< 0.001 vs. saline, ###p < 0.001 vs. METH.

Serotonin Assays. Figure 4.4 shows the effects of the sigma receptor ligand AZ66 and
methamphetamine on serotonin levels in the mouse striatum. ANOVA demonstrated no
significant differences between groups (q=1.12,p>0.05).
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Figure 4.4. Effects of methamphetamine (METH) and AZ66 on 5-HT levels in the mouse striatum. Male, Swiss
Webster mice (n = 6-8 per group) were pretreated with saline (SAL) or AZ66 (AZ, 10 mg/kg, i.p.). After 15 min, the
mice were then treated with saline (SAL) or METH (10 mg/kg, i.p.). This treatment schedule was repeated 4 times at
2 h intervals. One week later, the brain was removed and 5-HT levels were measured via ELISA. Data was reported
as mean ± SEM.

4.3.2 DAT Immunohistochemistry. To test the effects of AZ66 on methamphetamine-induced
DAT reductions, immunohistochemical analyses were conducted. Figure4.5 depicts the effects
of methamphetamine and AZ66 on DAT immunoreactivity in the mouse striatum, with a
significant difference between the treatment groups (F(3,38)=118.70, p<0.0001).Post-hoc
Tukey’s multiple comparisons tests confirmed that methamphetamine caused a significant
reduction in DAT immunoreactivity relative to treatment with saline alone (q=25.55, p<0.001).
Pretreatment with AZ66 significantly attenuated methamphetamine-induced neurotoxicity
(q=20.97, p<0.001), whereas treatment with AZ66 alone had no significant effects on DAT
expression compared to saline alone (q=3.65, p>0.05).
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Figure 4.5. Effects of methamphetamine (METH) and AZ66 on dopamine transporter immunoreactivity in the
mouse striatum. Male, Swiss Webster mice (n = 4 per group) were pretreated with saline (SAL) or AZ66 (AZ, 10
mg/kg, i.p.). After 15 min, the mice were then treated with saline (SAL) or METH (5 mg/kg, i.p.). This treatment
schedule was repeated 4 times at 2 h intervals. One week later, the brain was removed and stained for dopamine
transporter immunoreactivity. A representative section from each treatment group is shown, along with average
optical density readings (mean ± SEM). ***p< 0.001 vs. saline, ###p < 0001 vs. METH.

4.3.3 Hyperthermia. Methamphetamine produced a significant increase in body temperature,
which was attenuated by AZ66. One-way ANOVA showed significant differences between all
groups (F(3,15)=19.08, p<0.001). ANOVA of body temperature measured following each
treatment time point revealed significant changes in all but the first time point (BT1) (Fig. 4.6):
BT1 (F(3,39)=9.67, p>0.05); BT2 (F(3,39)=13.93, p<0.01); BT3 (F(3,39)=14.02, p<0.01); BT4
(F(3,39)=21.14, p<0.01). Post-hoc Tukey’s tests confirmed methamphetamine significantly
increased body temperature after the second injection onwards (BT2, q=8.09, p<0.001; BT3,
q=7.72, p<0.001; BT4, q=8.36, p<0.001).AZ66 significantly mitigated the hyperthermia effects of
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methamphetamine(BT3, q=5.20, p<0.01; BT4, q=5.11, p<0.01). When AZ66 was administered
in the absence of methamphetamine, ANOVA showed that there were no significant changes in
basal body temperature compared to saline treated animals (q=1.56, p>0.05).
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Figure 4.6. Effects of AZ66 on methamphetamine (METH)-induced hyperthermia. Male, Swiss Webster mice (n
= 6-8 per group) were pretreated with saline or AZ66 (10 mg/kg, i.p.), and after 15 min, the mice were treated with
saline or METH (5 mg/kg, i.p.). Core body temperature was measured 1 h after each injection combination. This
regimen was repeated four times at 2 h intervals. Data was reported as mean ± SEM. ***p< 0.001 vs. saline, ##p <
0.01 vs. METH.

4.4 Discussion
The selective sigma receptor ligand AZ66 has been optimized for metabolic stability and
tested against the stimulant effects of methamphetamine in our previous study (Seminerio et al.,
2012). The current study demonstrates that AZ66 has protective effects against
methamphetamine-induced dopaminergic neurotoxicity and hyperthermia.
Consistent with previous reports (Kaushal and Matsumoto, 2011; Nguyen et al., 2005) this
work also demonstrates that targeting sigma receptors can provide neuroprotective effects
against methamphetamine-induced neurotoxicity. While future studies will need to be conducted
to delineate the exact mechanism of this interaction, a number of hypotheses can begin to
explain the neuroprotective effects of sigma receptor ligands. Sigma receptors have been
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shown to modulate various neurotransmitter systems afflicted by methamphetamine
(Bastianetto et al., 1995; Guitart et al., 2004; Mishina et al., 2005). Specifically, our results
further emphasize a modulatory role of sigma receptors in the dopaminergic system and regions
of the brain responsible for dopamine transmission.
Dopamine depletions following methamphetamine administration appear primarily
dependent on dopamine transporter function (Cadet and Krasnova, 2009; Krasnova and Cadet,
2009; Schmidt et al., 1985). Animals lacking dopamine transporters are protected against
dopamine depletions (Fumagalli et al., 1998a; Fumagalli et al., 1998b; Giros et al., 1996). In
addition, striatal dopamine depletions are proportional to the degree of hyperthermia, which is
linked to methamphetamine-induced lethality (Bowyer et al., 1994). The selective sigma
receptor ligand, AZ66, was found to protect against methamphetamine-induced striatal
dopamine and dopamine transporter reductions as well as increases in body temperature.
These findings support previous studies that also demonstrate neuroprotective properties of
sigma receptor ligands (Kaushal et al., 2011; Matsumoto et al., 2008; Seminerio et al., 2011).
The mechanisms responsible for methamphetamine-induced neurotoxicity are complex and
involve multiple interacting and cascading processes: excessive release of monoamines like
dopamine; auto-oxidation of dopamine leading to reactive oxygen species (ROS) generation;
activation of endoplasmic reticulum (ER) stress pathways, mitochondrial death cascades, and
glutamatergic/N-methyl-d-aspartate (NMDA)-mediated excitotoxic mechanisms (Krasnova and
Cadet, 2009). Modulation of sigma receptors can alter similar processes in the other studied
systems: release of neurotransmitters such as dopamine (Bastianetto et al., 1995) protective
effects against ROS-related dysfunctions such as brain ischemia (Schetz et al., 2007);
regulation of ER stress and mitochondrial death cascades (Tsai et al., 2009) and modulation of
NMDA receptor function, including excitotoxic mechanisms (DeCoster et al., 1995; Shen and
Phillips, 1998; Shimazu et al., 2000). Therefore, AZ66 most likely provides neuroprotection by
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intervening at multiple points in the neurotoxic cascade of methamphetamine through sigma
receptors via a combination of competitive and non-competitive interactions.
In addition to the aforementioned mechanisms related to methamphetamine, targeting
sigma receptors has been reported to effectively attenuate neurotoxicity in several other models
including β-amyloid, carbon monoxide, and ischemic stroke (Marrazzo et al., 2005; Marrazzo et
al., 2006; Meunier et al., 2006). Furthermore, sigma receptors appear to play a role in animal
models of neuropsychiatric complications like depression, psychosis, cognitive and motor
deficits (Mishinet et al., 2005; Guitart et al., 2004), which are also observed in
methamphetamine users and have been associated with the neurotoxic effects of
methamphetamine (Cruickshank and Dyer, 2009). Therefore, the ability of AZ66 to mitigate
methamphetamine-induced neurotoxicity may have broader implications for other neurotoxic
and neuropsychiatric conditions.
Taken together with previous studies utilizing AZ66, we believe AZ66 represents a viable
lead compound for mitigating the effects of methamphetamine. Additional studies will need to be
conducted to further evaluate AZ66 as a therapeutic and characterize the role of sigma
receptors in the actions of methamphetamine.

4.5 Contributions
Michael Seminerio performed the dopamine and serotonin ELISA’S, the DAT
immunohistochemistry studies, and the hyperthermia studies.
AZ66 was synthesized by Ahmed Abdelazeem in Dr. Christopher McCurdy’s lab.
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CHAPTER 5
EVALUATION OF AZ66 AGAINST
METHAMPHETAMINE-INDUCED COGNITIVE
IMPAIRMENT
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5.1 Introduction
Methamphetamine is an abused drug which produces neurotoxic effects and psychiatric
complications (Cadet et al., 2003; Davidson et al., 2001). In addition, methamphetamine has
recently been shown to produce cognitive impairments (Hart et al., 2012).The role of
methamphetamine abuse in cognitive-related decline has remained controversial, however
current studies suggest while acute use of methamphetamine may actually improve memory
and attention; chronic use results in a decrease of memory and reaction speed. This effect has
been observed both in humans via clinical tests such as the Wisconsin card sorting test and
animals studies which evaluate maze sequential learning (Chapman et al., 2001), motor
performance (Walsh and Wagner, 1992), spatial impairment (Friedman et al., 1998) and object
recognition (Belcher et al., 2008; Bisagno et al., 2002; Kamei et al., 2006; O'Dell et al., 2011;
Reichel et al., 2012).It is hypothesized that methamphetamine use may increase an abusers
risk of neurodegenerative diseases such as Parkinson’s disease(Kuehn, 2011; Morrow et al.,
2011). Recently, it has been shown in a 15 year prospective study that methamphetamine
abuse results in a significantly higher risk of the development of Parkinson’s disease(Callaghan
et al., 2010). Currently there are no approved pharmacological treatments for the neurologic
deficits arising from methamphetamine abuse. Recent work showing a specific connection
between methamphetamine abuse and an increase risk of neurodegenerative diseases such as
Parkinson’s further emphasizes the need for pharmacotherapies aimed at treating these
consequences of methamphetamine abuse.
Previous work has demonstrated sigma receptors may be a viable target to attenuate some
of the effects of methamphetamine. Methamphetamine is known to interact with both subtypes
of sigma receptors at physiologically relevant concentrations(Nguyen et al., 2005) and sigma
receptors have been shown to be involved in many of the behavioral and physiological effects of
methamphetamine (Kaushal et al., 2012; Kaushal and Matsumoto, 2011; Kaushal et al., 2011;
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Matsumoto et al., 2008; Seminerio et al., 2011; Seminerio et al., 2012). Pretreatment with
selective sigma-1/sigma-2 receptor ligands such as AC927 (N-phenethylpiperdine oxalate)or
CM156 (3-(4-(4-cyclohexylpiperazin-1-yl)butyl)benzo[d]thiazole-2(3H)-thione) have been shown
to attenuate methamphetamine-induced hyperthermia, dopaminergic neurotoxicity, and
serotonergic neurotoxicity, in addition to mitigating some of the stimulant effects of
methamphetamine such as increases in locomotor activity (Kaushal et al., 2011; Matsumoto et
al., 2008). Sigma receptor ligands also exhibit protective effects in various models of cognitive
impairment (van Waarde et al., 2011) and sigma receptors are thought to have a functional role
in Parkinson’s disease (Mishina et al., 2005). The protective effects of sigma receptor ligands
against methamphetamine-induced neurotoxicity and cognitive impairment further validates
sigma receptors as potential targets for pharmacologic treatments against methamphetamine.
The current study utilizedAZ66 (3-(4-(4-cyclohexylpiperazin-1-yl)pentyl)-6flourobenzo[d]thiazol-2(3H)-one), a mixed sigma-1/sigma-2 ligand derived from CM156 and
optimized for metabolic stability (Seminerio et al., 2011), to determine its effects as a
pretreatment against methamphetamine-induced cognitive impairment. AZ66 has previously
been shown to mitigate many of the behavioral effects of methamphetamine, including the
development and expression of behavioral sensitization (Seminerio et al., 2012), suggesting its
potential importance toward future drug development studies. This study is the first to evaluate a
selective sigma receptor ligand for its ability to attenuate cognitive impairment following
repeated methamphetamine administration.

5.2 Materials and Methods
5.2.1 Memory Measurements. Mice (n=10/group) were randomly assigned to treatment
groups, which were the same as those described for the neurotoxicity studies. All of the
combinations of drug treatments were given i.p. at 2 h intervals a total of four times. Following
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one week, animals were evaluated for memory in the object recognition test and step-through
passive avoidance test. The detailed procedure for each of the tests is provided below.

5.2.2 Object Recognition Test. The test was carried out as described previously (Li et al.,
2011). Each mouse was allowed to move freely in an open-field box for 5 min as habituation.
Twenty-four hours later, mice were individually placed in the center of the box containing two
identical objects (Lego blocks) located in the two diagonal corners. The cumulative time spent
exploring each object was recorded during a 5 min period. Exploration was defined as actively
touching or facing (within 2 cm toward) the object. One day later (24 h after training), mice were
tested for memory using the same procedure except that one of the familiar objects was
replaced with a novel object. The time of exploration of each object [Tf and Tn for familiar (f) and
novel (n) objects, respectively] was recorded for determination of the recognition index (RI) =
Tn/(Tf+Tn).

5.2.3 Step-through passive avoidance test. The test was performed as described previously
(Zhang et al., 2005) with some modifications. The apparatus (Model E10-16SC; Coulbourn
Instruments, Allentown, PA) consisted of a two-compartment chamber with an illuminated
compartment connected to a darkened one by a guillotine door. The experiment consisted of
single training and testing sessions.
On the first day, the animal was placed in the chamber and allowed to roam freely between
the illuminated and darkened side for 5 min. During training (24 h later), the mouse was placed
in the illuminated compartment, facing away from the closed guillotine door, for 1 min before the
door was raised. The latency to enter the darkened compartment was recorded. After the
mouse entered the darkened compartment, the door was closed and an electric shock (0.4 mA,
5 s) was delivered from the steel-rod floor. This was repeated until the latency for the animal to
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enter the dark compartment exceeded 60 s once the door was open. The number of shocks the
animal received before meeting the >60 s criterion was also recorded.
Twenty-four hours later, mice began the testing session. To begin the test, the mouse was
again placed in the illuminated compartment, with the guillotine door closed for 1 min. Following
1 min, the door was opened and the retention latency to enter the darkened compartment was
recorded for up to 300 s, at which time the test was terminated. No shocks were delivered to
mice that entered the darkened compartment during the test trial.

5.2.4 Morris Water Maze. This test is used to assess spatial learning and memory following
procedures described previously (El-Ghundi et al., 1999) with slight modifications. In brief mice
are placed into a circular pool (95cm diameter x 25 cm high) with which a circular platform
(8.5cm diameter x 15.5cm high) is placed. The pool is then filled with water (21 ±1⁰ C) made
opaque by the addition of powdered milk. On the first day of the protocol, the visible cued
platform test is performed to control for sensory/motor abilities as well as motivation. Curtains
are closed around the pool to eliminate distal cues, and the water level is maintained so that the
platform is 1 cm above the water. A small red flag is then placed onto the platform and 4
controlled cue trials are run by placing the animal at random starting locations and being
allowed to escape by finding the platform which is placed at a new location for each trial. During
the acquisition trials which start the next day, the platform is submerged 1cm below the water's
surface and several extra-maze distal cues are placed on the curtains. The mice are then
trained for 15 trials over 3 days (6 trials on day one, 5 trials on day two, and 4 trials on day
three) to locate the hidden platform from different starting points (N, S, E, W, NW, and SE).
Twenty-four hours after the last training session, a probe trial is conducted where the platform is
removed and the animals are allowed to swim for 60 seconds. Latency to reach platform,
number of entries into the target quadrant/platform site, and time spent in the target
quadrant/platform site are analyzed to assess spatial memory.
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5.2.5 Data Analysis. The data from the object recognition test, step through passive
avoidance test, and Morris water maze were evaluated using one-way analysis of variance
(ANOVA).Post-hoc analyses were performed with Dunnett’s tests or Bonferroni’s tests for
comparisons to controls and Tukey’s tests for pairwise comparisons. For all analyses, p<0.05
was considered statistically significant. GraphPad Prism (San Diego, CA) was used for all data
analyses.

5.3 Results
5.3.1 Object Recognition. The effects of methamphetamine and AZ66 on recognition
memory were evaluated in Fig. 5.1. ANOVA showed significant difference between groups in
the object recognition test (F(3,31)=9.01, p<0.001). Post-hoc Tukey’s tests confirmed that
methamphetamine produced significant impairment of recognition memory when compared to
the saline control (q=7.04, p<0.001); this was reversed by pretreatment with AZ66 (q=5.31,
p<0.01). Animals treated with AZ66 alone showed no significant difference from saline-treated
animals (q=2.50, p>0.05).
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Figure 5.1. Effects of AZ66 on methamphetamine (METH)-induced memory impairment in the object
recognition test. Mice were pretreated with saline (SAL) or AZ66 (AZ, 10 mg/kg, i.p.). After 15 min, the mice were
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then treated with saline (SAL) or METH (5 mg/kg, i.p.). This treatment schedule was repeated 4 times at 2-h
intervals. One week later, the animals underwent the object recognition test. Data are reported as mean ± SEM; ***p
< 0.001 vs. saline; ##p< 0.01 vs. METH; n = 6-8 per group.

5.3.2. Step-through Passive Avoidance Test. Figure 5.2depicts the effects of
methamphetamine and AZ66 on memory using the step through passive avoidance test. No
significant effects were observed on the % entries required for acquisition of the passive
avoidance task during training (Fig. 5.2A) and the 24-h latency to enter the dark compartment
during testing (Fig. 5.2B) among any of the groups tested (F(3,31)=1.03, p>0.05). However,
while not significant, these results demonstrate a similar trend as that seen with the object
recognition in which animals treated with methamphetamine alone showed increased entries
into the dark compartment during the testing period and decreased latency during the testing
period. These tendencies were reduced by pretreatment with AZ66.
B

A
100
300

Latency to Enter (s)

Entries (%)

80
60
40
20
0
Sal/Sal Sal/METH

AZ/Sal

257

252
217

244

200

100

0

AZ/METH

Sal/Sal Sal/METH

AZ/Sal

AZ/METH

Figure 5.2. Effects of AZ66 on methamphetamine (METH)-induced cognitive impairment in the stepthrough
passive avoidance test. Mice were pretreated with saline (SAL) or AZ66 (AZ, 10 mg/kg, i.p.). After 15 min, the mice
were then treated with saline (SAL) or METH (5 mg/kg, i.p.). This treatment schedule was repeated 4 times at 2 h
intervals. One week later, the animals underwent the step-through passive avoidance test. Animals were observed for
(a) % entries into the dark compartment during training and (b) latency to enter dark compartment. Data was reported
as mean ± SEM, no significant changes were observed; n = 6-8 per group.

5.3.3 Morris Water Maze. Figures 5.3 depicts the effects of methamphetamine and AZ66 in
the visible platform test and figure 5.4 represents the average time to find the platform during
training. No significant effect was observed in time to reach platform and the average latency to
find the platform between any of the groups tested (Fig 5.3, p=0.7026; Fig 5.4, p=0.0982).
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Figure 5.3. Morris water maze visible platform test. Mice were evaluated for their time to reach the visible platform
following treatment with methamphetamine (METH) and AZ66.
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Figure 5.4. Morris water maze training. Mice were evaluated for their latency to find the platform during training on
day 1 (6 trials), day 2 (5 trials) and day 3 (4 trials) following administration of methamphetamine (METH) and AZ66.
The points represent an average for each group on each day.

Figure 5.5 depict the effects of methamphetamine and AZ66 on additional endpoints
measured in the Morris water maze. Similarly to the time to reach platform, no significant effects
were found in any of the other endpoints tested: velocity (Fig. 5.5A, p=0.2115), average latency
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to find platform (Fig. 5.5B, p=0.2311), % entries in target quadrant (Fig. 5.5C, p=0.3595), and %
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Figure 5.5. Effects of AZ66 and methamphetamine in the Morris water maze probe test.Mice were evaluated for
their velocity (A), latency to platform (B), % entries in target quadrant (C) and % time in target quadrant (D) following
treatment with methamphetamine (METH) or AZ66. TQ= target quadrant.

5.4 Discussion
The current study demonstrates AZ66 has protective effects against methamphetamineinduced cognitive impairments in the object recognition test however no significant effects were
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observed in the step-through passive avoidance test or Morris water maze test. These results
appear to be consistent with previous reports showing the effects of methamphetamine on
cognition (Hart et al., 2012;(Herring et al., 2008). Additionally, AZ66 was previously shown to
attenuate methamphetamine-induced dopaminergic neurotoxicity (unpublished data) which may
suggest a mechanism for some of the protective effects of sigma receptor ligands against
methamphetamine-induced cognitive impairment.
With evidence beginning to link methamphetamine exposure to the development of
Parkinson’s disease, dopaminergic neurotoxicity remains a central theme. A myriad of studies
have shown methamphetamine produces significant depletions of dopamine levels and
dopamine transporters in both human and animal models (Cadet and Krasnova, 2009; Kita et
al., 2003; Morrow et al., 2011; Schmidt et al., 1985; Volkow et al., 2001a; Volkow et al., 2001c;
Wilson et al., 1996). While the majority of research has been dedicated to the acute effects of
methamphetamine on cognitive function (some showing an increase in cognitive function
following low to moderate doses), less is known regarding the long term effects of repeated
methamphetamine abuse on cognition. The following paragraphs will explore the relationship
between repeated methamphetamine abuse and its effects on cognition and the dopaminergic
system while illustrating the importance of sigma receptors.
A number of neurotransmitter systems are likely involved in methamphetamine-induced
cognitive impairments, however methamphetamine is likely to act primarily on the dopaminergic
system (Gough et al., 2002; Han and Gu, 2006; Kuczenski et al., 1995). Dopamine has been
shown to modulate different cognitive functions including memory, attention, task switching and
response inhibition (Cohen and Servan-Schreiber, 1993; Nordahl et al., 2003). Furthermore,
dopamine deficits in regions of the striatum have been shown to reduce reaction time and
simple task performance (Baunez and Robbins, 1999; Nordahl et al., 2003)while DA deficits in
the prefrontal cortex also contribute to cognitive dysfunction (Baunez and Robbins, 1999;
Roberts et al., 1994; Rogers et al., 1999). Methamphetamine is known to affect both the
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striatum and prefrontal cortex (Cadet and Krasnova, 2009; Kita et al., 2003) and sigma
receptors are expressed in both of these regions (Guitart et al., 2004; Hayashi et al., 2010).
Moreover, sigma receptors are present on dopamine neurons and can modulate their function
(Bastianetto et al., 1995) suggesting a potential mechanism for the neuroprotective effects of
AZ66.
The striatum plays an important though often forgotten role in cognition. It has been
shown that the striatum cooperates with the hippocampus in the formation of episodic memories
(Sadeh et al., 2011). Also, episodic memories are often impaired in persons with Parkinson’s
disease and subsequent dopaminergic-striatal deficiencies (Altgassen et al., 2007; Beste et al.,
2009). Dopamine plays a strong role in the formation of episodic memories like that seen in the
object recognition test (Hotte et al., 2005). Therefore, it should come as no surprise that
neurotoxic doses of methamphetamine which significantly lower striatal dopamine levels impair
object recognition memory (Belcher et al., 2008; Bisagno et al., 2002; Kamei et al., 2006; O'Dell
et al., 2011; Reichel et al., 2012; Schroder et al., 2003). In this study, pretreatment with AZ66
significantly attenuated the effects of methamphetamine administration on object recognition
memory. We believe this is through the neuroprotective properties of sigma receptors, as
pretreatment with AZ66 also resulted in attenuation of methamphetamine-induced dopaminergic
neurotoxicity in the striatum and sigma receptors are highly expressed in the striatal regions of
the brain (Guitart et al., 2004; Hayashi et al., 2010). It is also possible that protection of these
necessary striatal dopamine stores resulted in increased object recognition memory via an
indirect modulatory role on glutamatergic transmission. It has previously been shown that
striatal dopamine plays a role in modulating glutamatergic signaling(Marti et al., 2002;
Yamamoto and Davy, 1992)and that glutamatergic signaling in the striatum plays a very
important role in object recognition memory (Roullet et al., 2001; Sargolini et al., 2003).
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The pharmacology and neuroanatomy of object recognition memory is very complex,
and can rely upon many brain regions and neurotransmitters, however recent research has
implicated the perirhinal cortex as an important brain region responsible for object recognition
memory (Reichel et al., 2012; Wan et al., 1999; Warburton and Brown, 2010). While projections
between the prefrontal cortex and hippocampus are thought to contribute to cognitive memory
formation(Hirai et al., 2012; Miyashita and Chang, 1988), the prefrontal cortex does not directly
project to the hippocampus, but rather to the perirhinal cortex and amygdala(Burwell, 2001;
Furtak et al., 2007; Hirai et al., 2012).In addition to being expressed in the prefrontal cortex,
sigma receptors are also located in the amygdale (Hayashi et al., 2010) and may play a
modulatory role in cognition in these areas (Wang et al., 2007). The role of the hippocampus in
object recognition remains controversial; however the putative role is believed to be evoked
when spatial cues or landmarks present in the room are used by animals while in the testing
chamber(Morris and Frey, 1997). Since our object recognition testing chamber was enclosed
within curtains, the effects of distal landmarks and the role of the hippocampus in our behavioral
protocol should therefore be minimized.
Consistent with the findings in object recognition, the step through passive avoidance
test also produced memory patterns in a similar trend; however the results were not significant.
It has been shown that dopamine plays a strong role in different brain regions involved with the
regulation of inhibitory avoidance memory. In the striatum, pharmacological blockade of
dopamine receptors decreased step through passive avoidance memory (Manago et al., 2009).
Dopamine infused into the amygdala post training increased passive avoidance memory, while
dopamine receptor antagonists impaired retention (Lalumiere et al., 2004). In addition, the
dopamine uptake inhibitor GBR 12783 injected before training was found to significantly
improve passive avoidance memory in rats (Nail-Boucherie et al., 1998). We believe one
reason for the lack of significant results may be due to the strength of emotional memory
created by our behavioral paradigm. Emotional memory or fear memory is one of the strongest
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forms of memory, and also the easiest to learn. While normal “fear” conditioning is typically
considered to be classical condition tests such as contextual fear conditioning, it is hard to deny
the strong emotional fear aspect that results from the administration of a nociceptive shock seen
during step through passive avoidance. In our behavioral protocol, the mice received a
moderately large intensity and duration shock (.4mA/5seconds). While this makes the training
portion of the protocol easier, it can also have the confounding effect of making the memory
stronger in all the treatments, resulting in a ceiling effect which may mask the promnesic effects
of the experimental variable or treatment (Nail-Boucherie et al., 1998; Rossato et al., 2009). We
hypothesize that training the animals with a decreased intensity and duration of a shock
(.3mA/2-3 seconds) may have resulted in less “extreme” of a memory, and thus allowed more
significance to be observed twenty-four hours later during our testing paradigm. Nevertheless,
our results, taken with the object recognition data, suggest methamphetamine may produce
some of its cognitive effects through sigma receptors.
The effects of methamphetamine and AZ66 on memory impairment using the Morris
water maze, a hippocampal dependent task (Morris et al., 1982), were also evaluated.
Consistent with previous reports (Herring et al., 2008), methamphetamine produced no
significant impairments when compared with saline treated animals in any of the endpoints
tested. In addition, AZ66 was found to have no effect on any of the endpoints tested. Given this
effect, taken with other tests herein, it is possible to functionally separate effects on path
integration from spatial mapping despite neural network overlap (Herring et al., 2008; Whishaw
et al., 1997). Previous work has demonstrated a significant impairment following
methamphetamine administration using the Cincinnati water maze, a test employed to assess
path integration learning (Herring et al., 2008), however the role of sigma receptors in this effect
has yet to be determined.
In conclusion, the optimized selective sigma receptor ligand AZ66 was found to
significantly attenuate cognitive impairment in the object recognition test induced by repeated
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exposure to methamphetamine. This study supports a role for sigma receptors in the cognitive
effects of methamphetamine while further validating AZ66 as a potential lead compound.
Future studies will need to be conducted to further characterize the role of sigma receptors in
methamphetamine-induced cognitive impairment. However, our studies taken with previous
literature suggests sigma receptors represent a promising target for the development of novel
therapeutics aimed at alleviating a multitude of effects produced by methamphetamine.

5.5 Contributions
Michael Seminerio and Rolf Hansen performed the object recognition test, step through passive
avoidance test, and Morris water maze test.
AZ66 was synthesized by Ahmed Abdelazeem in Dr. Christopher McCurdy’s lab.
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CHAPTER 7
CONCLUSIONS AND FUTURE
STUDIES/DIRECTIONS
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8.1 Summary
In summary, the studies that have been presented herein demonstrate the following:
 Structural optimizing CM156 for metabolic stability had no effect on its pharmacological
profile
 AZ66 attenuates acute methamphetamine locomotor hyperactivity via two routes of
administration
o
o

Intraperitoneal
Per os (oral)

 AZ66 significantly reduced the expression and development of behavioral sensitization
evoked by subchronic exposure of methamphetamine
 AZ66 significantly attenuated methamphetamine-induced dopaminergic neurotoxicity
and hyperthermia but had no effect on serotongeric neurotoxicity
 Neurotoxic dosing with methamphetamine caused significant memory impairment in the
object recognition test which was attenuated when animals were pretreated with AZ66;
similar trends were observed in the step-through passive avoidance test

8.2 Future studies and directions
8.2.1 Future studies involving the actions of sigma receptors in the actions of
methamphetamine. Of the many future studies that will need to be conducted to further evaluate
the role of sigma receptors in the actions of methamphetamine, self administration studies
would be a priority. While previous work has demonstrated the addictive properties of
methamphetamine using animal self administration models (Niwa et al., 2008; Pickens et al.,
2011), the role of sigma receptor ligands in these effects remain to be elucidated. These studies
would provide great insight into understanding the addictive properties of methamphetamine
and the function of sigma receptors in methamphetamine related addiction.
It will also be important to delineate the role of sigma receptor subtypes in
methamphetamine-induced effects. As of now, the sigma-2 receptor has yet to be cloned and
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we are currently lacking any sigma-2 selective compounds (based on >100 fold selectivity
criteria). With the addition of a selective sigma-2 ligand, characterization of each subtype
function will be easier to evaluate. The same can be said for the development of a functional
assay to definitively determine whether compounds have agonist or antagonists properties at
sigma receptors.
Lastly, with recent evidence beginning to link methamphetamine abuse to Parkinson’s
disease (Callahan et al., 2010) it will be important to study the effects of sigma receptor ligands
on methamphetamine-induced cognitive impairments. While a small set of studies were
performed in our lab, a number of future studies will need to address the various aspects of
memory and learning (i.e. spatial and sequential) following methamphetamine exposure and the
involvement of sigma receptors in these effects.

8.2.2. Future directions for methamphetamine related studies. Development of therapeutics
for treating the effects of methamphetamine has been largely unsuccessful to this point in time.
Research seeking improved translation of treatments from bench-to-bedside for
methamphetamine abuse, whether acute or chronic, likely needs to address not only selection
of the most appropriate therapeutic target but also the relevance of preclinical models. The
disconnect between preclinical studies and clinical reality likely needs to be addressed going
forward. Many preclinical studies employ therapeutics prior to drug administration or shortly
thereafter. Clearly, this is not nearly as clinically relevant as treatment administration a number
of hours after methamphetamine dosing. To truly address the effects of methamphetamine, the
compound needs to be administered following the onset of symptoms of significant enough
severity that they would generally lead to an individual seeking treatment, whether that be
voluntarily or involuntarily. Furthermore, while the majority of neurotoxic and hyperthermia
studies use a high dose binge regimen; this may not be the best paradigm to mimic real life
abusers. Methamphetamine users tend to gradually increase stimulant doses of the drug rather
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than start and remain at a high dose (Segal et al., 2003). Rarely do drug abusers use the same
dose multiple times a day suggesting current preclinical models should be designed more in a
exponential like dosing scheme.
The role of temperature in methamphetamine-induced effects has been clearly shown in
preclinical models yet pre-clinical studies continue to be conducted at standard laboratory
temperatures despite the realization that exposure by abusers rarely occurs in a standardized
environment (Miller and O'Callaghan, 1994, 2003). Similarly, preclinical studies often fail to
address other factors leading to increased magnitude or duration of hyperthermia and
associated neurotoxicity following methamphetamine abuse, such as social interaction. This is
particularly relevant for therapeutic development and timing of administration based on
preclinical work illustrating that while social interaction didn’t result in an increased magnitude of
hyperthermia, the duration of elevated body temperature persisted for a longer duration(Brown
et al., 2003). While this may be difficult to incorporate into the experimental design, it is
important to understand the effects of external environment may play a significant role in the
effects of methamphetamine.
Nearly all pre-clinical studies using methamphetamine administer the drug independently
despite the predominant use of methamphetamine in conjunction with alcohol (Kirkpatrick et al.,
2012). In fact, this combination accounts for 24% of all emergency department visits related to
methamphetamine use. While preclinical studies have addressed the interaction of alcohol with
other stimulants, often demonstrating significant differences in physiologic parameters
compared to either drug alone, little remains known concerning the interaction of
methamphetamine and alcohol in commonly used animal models. Understanding this
interaction may be important in future therapeutic development, particularly considering recent
evidence indicating differing effects clinically when methamphetamine and alcohol are
administered in combination compared to administration of either drug alone (Kirkpatrick et al.,
2012).
87

Differences in the way methamphetamine is abused clinically compared to the design of
many preclinical studies present another parameter that can be adjusted to more appropriately
represent the clinical reality. For example, preclinical studies often utilize repeated dosing over
subsequent days to simulate chronic abuse. While this may be representative of one episode of
use in humans, in which the drug is typically abused for a period of approximately four days
before a period of abstinence, this is not entirely representative of true chronic use as patients
often abuse methamphetamine over the course of months/years. (Itzhak and Achat-Mendes,
2004) It is likely that these different dosing strategies will be required to not only study both
acute and chronic effects of various use patterns but the mechanisms of neurotoxicity
associated with each may vary(Davidson et al., 2001).
Finally, additional work should address the interaction of the periphery with the central
nervous system-mediated effects. Methamphetamine use results in systemic physiologic
alterations and it is likely that combination therapies targeting multiple injurious
mechanisms/pathways may be more successful in comparison to monotherapy. Modulation of
inflammatory processes has proven successful in mitigating other pathologic conditions and this
may be true of methamphetamine-induced hyperthermia but requires future study investigating
why preclinical studies illustrate a clear disconnect between neuroinflammation and
neurotoxicity in some cases but not others (Cadet et al., 2003; Itzhak and Achat-Mendes, 2004;
O'Callaghan et al., 2008; Zhang et al., 2006).
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2011
Search Committee: Assistant Director of Research and Graduate Education
Student representative
2011-2012
Society for Neuroscience- West Virginia Regional Chapter
Secretary
2011-2012
Selection Committee for Behavioral and Biomedical Sciences Scholarship
Co-Chair
2011-2012
West Virginia University Health SciencesGraduate Student Organization
President
2011-2013
ASPET Graduate Recruitment and Education Committee
National Student Representative
2012-Present ASPET Institutional SURF Fellowship Review
Grant Reviewer

PEER REVIEWED PUBLICATIONS
1.

Stavitskaya L, Seminerio MJ, Matthews-Tsourounis MM, Matsumoto RR, Coop A
(2010)The effect of the pyridyl nitrogen position in pyridylpiperzine sigma ligands. Bioorg
Med Chem Lett 20:2564-2565.
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2.

3.

4.
5.
6.
7.
8.
9.
10.
11.

12.
13.
14.

15.

Seminerio MJ, Kaushal N, Shaikh J, Huber J, Coop A, Matsumoto RR (2011) Sigma
receptor ligand AC927 (N-phenethylpiperdine oxalate) attenuates methamphetamineinduced hyperthermia and serotonin damage in mice. Pharmacol Biochem Behav 98:1220.
Kaushal N, Seminerio MJ, Shaikh J, Medina M, Wilson L, Mesangeau C, McCurdy CR,
Matsumoto RR (2011)A novel substituted piperazine, 3-(4-(4-cyclohexylpiperazin-1yl)butyl)benzo[d]thiazole-2(3H)-thione (CM156), attenuates the stimulant and toxic effects
of methamphetamine in mice. Neuropharm 61:992-1000.
Robson MJ, Elliott M, Seminerio MJ, Matsumoto RR (2011) Evaluation of sigma receptors
in the antidepressant-like effects of ketamine in vitro and in vivo. Eur J Neuropsychopharm
22:308-317.
Mesangeau C, Amata E, Alsharif E, Seminerio MJ, Robson MJ, Matsumoto RR, Poupaert
JH, McCurdy CR (2011) Indole-based selective sigma-2 receptor ligands: Synthesis and
pharmacological evaluation. Eur J Med Chem 46:5154-5161.
Seminerio MJ, Mesangeau C, McCurdy CM, Matsumoto RR (2011) Pharmacological
evaluation of an optimized analog of CM156; effects on methamphetamine.AAPS J 18:902919.
Robson MJ, Noorkbakhsh B, Seminerio MJ, Matsumoto RR (2011) Sigma-1 receptors:
Potential targets for the treatment of substance abuse. Curr Pharm Des 18:902-919.
Turner RJ, Seminerio MJ, Naser ZJ, Matsumoto RR, Rosen CL, Huber JD (2011) Effect of
age on behavioral assessment performance-implications for an aged stroke model. J
Neurosurg, Accepted.
Seminerio MJ, Robson MJ,McCurdy CR, Matsumoto RR (2012) Sigma receptor ligands
attenuate acute methamphetamine-induced hyperthermia but do not modulate IL-1β mRNA
expression in the hypothalamus. Eur J Pharm, Submitted.
Seminerio MJ, Turner R, Robson MJ, O’Callaghan J, Miller D, Matsumoto RR (2012) The
effects of methamphetamine on body temperature: a comprehensive review. Pharmacol
Ther, invited review, Submitted.
Seminerio MJ, Hansen R, Kaushal N, Abdelazeem AH, Mesangeau C, McCurdy CM,
Matsumoto RR (2012) The evaluation of AZ66, an optimized sigma receptor ligand, against
methamphetamine-induced dopaminergic neurotoxicity and cognitive impairment.Intl J
Neuropsychopharma, Submitted.
Kaushal N, Seminerio MJ, Robson MJ, McCurdy CR, Matsumoto RR (2012)
Pharmacological evaluation of SN79, a sigma receptor ligand against methamphetamineinduced neurotoxicity in mice. Eur J Neuropsychopharm,In preparation.
Noorbakhsh B, Seminerio MJ, Kaushal N, Xu YT, Healy JR, Mesangeau C, McCurdy CR,
Matsumoto RR (2012) Pharamcolgoical characterization of sigma-2 preferring compounds:
modulation of psychostimulant-induced effects. JPET, In preparation.
Abdelazeem AH,Mesangeau C,Jamalapuram S, Avery BA, Abbas S,Seminerio MJ,
Matsumoto RR, Poupaert JH, McCurdy CM (2012) Design and synthesis of metabolically
stable benzothiazolonone derivatives of CM156 with high affinity and selectivity for sigma
(σ) receptors. J Med Chem, In preparation.
Stavitskaya L*, Seminerio MJ*, Noorkbakhsh B, Healy J,Bowen W, Matsumoto RR, Coop
A (2012) The effect of partial opioid structures on sigma receptors. J Med Chem, In
preparation.

ABSTRACTS/POSTER PRESENTATIONS (SELECTED)
1.Seminerio MJ, Bayline R (2006) Development of innervations in the tergosternal muscle of
the moth Manduca sexta based on physiological activity. 28th Annual Western
Pennsylavania Biology Undergraduate Research Symposium, Pittsburgh, PA. (podium talk
and poster presentation)
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2.

Seminerio MJ, Kaushal N, Medina M, Shaikh J, McCurdy CR, Matsumoto RR (2008)
CM156, a novel sigma receptor antagonist, attenuates the neurotoxic effects of
methamphetamine in mice.
4th Annual West Virginia COBRE/INBRE Conference,
Morgantown, WV. (poster presentation)
3. Seminerio MJ, Kaushal N, Shaikh J, Medina M, McCurdy CR, Coop A, Matsumoto RR
(2009) Sigma antagonists, AC927 and CM156, protect againstmethamphetamine-induced
serotonergic neurotoxicity while attenuating hyperthermia. 71st Annual College on
Problems of Drug Dependence (CPDD) Meeting, Reno, NV. (poster presentation)
4. Seminerio MJ, Abdelazeem A, McCurdy CR, Matsumoto RR (2009) Characterization of
potentially stable analogs of CM156, a sigma receptor antagonist. 3rd Annual West Virginia
University Center for Neuroscience Retreat, Morgantown, WV. (poster presentation)
5. Seminerio MJ, Abdelazeem A, McCurdy CM, Matsumoto RR (2010) Characterization of
optimized CM156 analogs: A potential aid in the treatment of psychostimulant-induced
complications. STaR Symposium, Huntington, WV. (poster presentation)
6. Seminerio MJ, Mesangeau C, Avery BA, McCurdy CM, Matsumoto RR (2011)
Pharmacological evaluation of novel sigma receptor ligands against psychostimulantinduced effects. STEM: Science and Technology Research Day, Morgantown, WV. (poster
presentation)
7. Seminerio MJ, Kaushal N, Shaikh J, Mesangeau C,Abdelazeem A, Narayanan S, Coop A,
McCurdy CM, Matsumoto RR (2011) Sigma receptor ligands attenuate methamphetamineinduced neurotoxicity, International Drug Abuse Research Society (IDARS) Meeting, poster
presentation, Istanbul, Turkey, August 2011.
8. Seminerio MJ, Abdelazeem A, Avery BA, McCurdy CR, Matsumoto RR (2011) An
optimized sigma receptor ligand attenuates the behavioral effects of methamphetamine,
American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, Washington
DC, October 2011.
9. Seminerio MJ, AbdelazeemA, AveryB, McCurdyCM, MatsumotoRR (2011)The evaluation of
an optimized sigma receptor ligand on methamphetamine-induced dopaminergic
neurotoxicity and hyperthermia, Society for Neuroscience (SfN) Annual Meeting,
Washington DC, November 2011.
10. Seminerio MJ, Robson MJ, MesangeauC, McCurdy CR, Matsumoto RR (2012) Sigma
receptor ligands attenuate methamphetamine-induced hyperthermia but do not modulate
IL-1β mRNA expression in select brain regions, Experimental Biology Annual Meeting, San
Diego, CA, April 2012.

INVITED TALKS/SEMINARS
1.
2.
3.
4.
5.

“Evaluating novel sigma receptor ligands as potential pharmacological treatments,”
Department of Biology, Washington and Jefferson College, Washington, PA, 2009.
“The role of sigma receptors in psychostimulant-induced complications” Program in Cancer
Biology, West Virginia University, Morgantown, WV, 2010.
“Searching for the next big drug,” Introduction to Research elective, School of Pharmacy,
West Virginia University, Morgantown, WV, 2010.
“Pharmacological evaluation of novel sigma receptor ligands against psychostimulantinduced effects,” Van Liere Research Day Convocation, West Virginia University,
Morgantown, WV, 2011
“Pharmacological evaluation of an optimized analog of CM156; effects on
methamphetamine,” Postdoctoral recruitment event, Vanderbilt University, Nashville, TN,
2011.
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6. “An optimized selective sigma receptor ligand attenuates the behavioral effects of
methamphetamine,” International Drug Abuse Research Society (IDARS), invited speaker,
Istanbul, Turkey, August 2011.
7. “The evaluation of AZ66, an optimized sigma receptor ligand, against the behavioral effects
of methamphetamine,” Center for Clinical and Translation Science (CCTS), invited oral
presentation, Lexington, Kentucky, March 2012.

TEACHING ASSISTANT





Introduction to Research
Immunology and Biotechnology
Clinical Pharmacokinetics
Chemistry of Drug Action

PROFESSIONAL SOCIETY MEMBERSHIPS







American Association for Pharmaceutical Scientists
American Society for Pharmacology and Experimental Therapeutics
College on Problems of Drug Dependence
International Drug Abuse Research Society
Society for Neuroscience
Rho Chi – National Honor Society in Pharmacy

AWARDS












Valuable Contributions to West Virginia University School of Pharmacy, 2009, 2010, 2011
Biomedical and Behavioral Sciences Training Scholarship, 2009-2010
E.J. Van Liere Poster Presentation Award - First Place, 2010
Appointment to Biomedical and Behavioral Sciences T32 Training Grant, 2010-2012
Presenter for STaR Symposium (one of 10 graduate students selected from 560 abstract
submissions), 2010
Robert E. Stitzel Graduate Student Award – Outstanding Achievement and Professional
Development Award, 2010
E.J. Van Liere Poster Presentation Award - Second Place, 2011
Selected participant for the Vanderbilt University Postdoctoral Recruitment event, 2011
Outstanding Achievement Award, West Virginia University School of Pharmacy, 2011
Drug Design and Discovery Travel Award, American Association of Pharmaceutical
Scientists, 2011
Graduate Student Travel Award, American Society for Pharmacology and Experimental
Therapeutics, Experimental Biology, 2012
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